US20050112021A1 - Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light - Google Patents

Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light Download PDF

Info

Publication number
US20050112021A1
US20050112021A1 US10/904,361 US90436104A US2005112021A1 US 20050112021 A1 US20050112021 A1 US 20050112021A1 US 90436104 A US90436104 A US 90436104A US 2005112021 A1 US2005112021 A1 US 2005112021A1
Authority
US
United States
Prior art keywords
light
fluid
photosensitizer
radiation
treatment chamber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/904,361
Inventor
Dennis Hlavinka
Raymond Goodrich
Laura Goodrich
Daniel McGraw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo BCT Biotechnologies LLC
Original Assignee
Gambro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/596,429 external-priority patent/US7094378B1/en
Priority claimed from US09/962,029 external-priority patent/US20020015662A1/en
Application filed by Gambro Inc filed Critical Gambro Inc
Priority to US10/904,361 priority Critical patent/US20050112021A1/en
Publication of US20050112021A1 publication Critical patent/US20050112021A1/en
Assigned to GAMBRO BCT, INC. reassignment GAMBRO BCT, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GAMBRO, INC.
Assigned to NAVIGANT BIOTECHNOLOGIES, LLC reassignment NAVIGANT BIOTECHNOLOGIES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GAMBRO BCT, INC.
Priority to US11/840,759 priority patent/US9044523B2/en
Assigned to CARIDIANBCT BIOTECHNOLOGIES, LLC. reassignment CARIDIANBCT BIOTECHNOLOGIES, LLC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NAVIGANT BIOTECHNOLOGIES, LLC
Assigned to CITICORP TRUSTEE COMPANY LIMITED reassignment CITICORP TRUSTEE COMPANY LIMITED IP SECURITY AGREEMENT SUPPLEMENT Assignors: CARIDIANBCT BIOTECHNOLOGIES, LLC
Assigned to CARIDIANBCT BIOTECHNOLOGIES, LLC reassignment CARIDIANBCT BIOTECHNOLOGIES, LLC RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CITICORP TRUSTEE COMPANY LIMITED, AS SECUIRTY AGENT
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/24Apparatus using programmed or automatic operation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/603Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/18Erythrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029Radiation
    • A61L2/0076Radiation using a photocatalyst or photosensitiser
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088Liquid substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08Radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08Radiation
    • A61L2/10Ultra-violet radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/26Accessories or devices or components used for biocidal treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00Compounds containing elements of Groups 6 or 16 of the Periodic System
    • C07F11/005Compounds containing elements of Groups 6 or 16 of the Periodic System compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic System
    • C07F13/005Compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/02Iron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00Metallocenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029Radiation
    • A61L2/0047Ultraviolet radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/10Apparatus features
    • A61L2202/14Means for controlling sterilisation processes, data processing, presentation and storage means, e.g. sensors, controllers, programs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20Targets to be treated
    • A61L2202/22Blood or products thereof

Definitions

  • Blood screening procedures may miss pathogenic contaminants, and sterilization procedures which do not damage cellular blood components but effectively inactivate all infectious viruses and other microorganisms have not heretofore been available.
  • pathogen inactivating agents include certain photosensitizers, or compounds which absorb light of defined wavelengths and transfer the absorbed energy to an energy acceptor, have been proposed for inactivation of microorganisms found in blood products or fluids containing blood products.
  • photosensitizers may be added to the fluid containing blood or blood products and irradiated.
  • the photosensitizers which may be used in this invention include any photosensitizers known to the art to be useful for inactivating microorganisms.
  • a “photosensitizer” is defined as any compound which absorbs radiation at one or more defined wavelengths and subsequently utilizes the absorbed energy to carry out a chemical process.
  • Examples of photosensitizers which may be used for the reduction of pathogens in blood or blood products include porphyrins, psoralens, dyes such as neutral red, methylene blue, acridine, toluidines, flavine (acriflavine hydrochloride) and phenothiazine derivatives, coumarins, quinolones, quinones, and anthroquinones.
  • U.S. Pat. No. 5,762,867 is directed toward a system for activating a photoactive agent present in a body fluid with light emitting diodes (LEDs).
  • LEDs light emitting diodes
  • U.S. Pat. No. 5,527,704 is directed toward an apparatus containing LEDs used to activate a fluid containing methylene blue.
  • U.S. Pat. No. 5,868,695 discloses using LEDs having a red color and emitting light at a wavelength of 690 nm in combination with benzoporphrin derivative photosensitizers to inactivate red blood cells.
  • red blood cells are essentially transparent to radiation, and as such, the benzoporphorin derivatives absorb radiation at this wavelength to become activated.
  • LEDs having a blue color and emitting light at a peak wavelength of 425 nm to inactivate platelets.
  • U.S. Pat. No. 5,658,722 discloses irradiating platelets using UVA1 light having an emission peak near 365 nm. This patent teaches that damage to platelets is caused by short UVA ⁇ 345 nm, and unlike the present invention, calls for removing UVA wavelengths below 345 nm.
  • the present invention is directed toward the reduction of pathogens which may be present in blood or blood products using light having peak wavelengths in combination with an endogenous photosensitizer.
  • the present invention provides a method and apparatus for irradiating a fluid containing blood products and pathogens, together with a photoactive agent.
  • the fluid is exposed to light having a peak wavelength which is chosen to activate both the photoactive agent as well as to penetrate the fluid containing the specific blood product to inactivate any pathogens contained in the fluid.
  • One embodiment useful with the methods of the present invention is a radiation or treatment chamber having includes a bank or banks or arrays of lights, which emit light at an approximate peak wavelength of 470 nm, which is suitable for irradiating a red blood cell product.
  • Another embodiment of the present invention includes use of light emitted at an approximate peak wavelength of 308 nm, which is suitable for irradiating a platelet or plasma product.
  • a radiation enhancer such as a second radiation source or a reflective surface may be included in the radiation or treatment chamber.
  • the radiation enhancer may be placed adjacent to the container containing the fluid to be irradiated or opposite the radiation source to increase the amount of radiation contacting the fluid within the container.
  • the radiation or treatment chamber may also preferably include a means for producing movement in the fluid to be irradiated. Movement provides many benefits including improvement of the efficiency of the irradiation process by helping mix the photosensitizer with the fluid to be pathogen inactivated to provide turnover of the fluid within the container at the container-light interface.
  • Positioning the fluid to be irradiated so that it receives energy of sufficient wavelength and power to reduce pathogens contained in the fluid may include a support platform, a shelf or a tray for the sample to be disposed upon; an opening or gap between two supports which may be a light or light arrays, where the fluid within the container is positioned between the supports; or other means known in the art.
  • the support platform may move in a substantially horizontal manner as in a conveyer line, or may oscillate or agitate.
  • a support platform which may move in a substantially vertical plane or any angle therebetween may also be used.
  • the fluid-holding support platform or surface may be transparent to one or more of the wavelengths of light applied.
  • the fluid within the container may also be placed on the support surface between two or more sources of radiation, in a sandwich-like configuration.
  • FIG. 1 is a cross-sectional view of a treatment chamber which may be used in the present invention.
  • FIG. 2 is a cross-sectional view of a treatment chamber like that of FIG. 1 , but with an alternative reflective surface that may also be used in the present invention.
  • FIG. 3 is a graph depicting the absorption spectrum of riboflavin.
  • FIG. 4 is a graph depicting the absorption spectrum of hemoglobin at various concentrations.
  • FIG. 5 is a plan view of an array of LEDs that may be used in the present invention.
  • FIG. 6 is a graph depicting the light spectrum of one type of fluorescent bulb which may be used in the present invention as compared to a broad band type of bulb.
  • FIG. 7 is a graph comparing virus inactivation as a function of energy.
  • FIG. 8 is another graph comparing virus inactivation as a function of energy.
  • FIG. 9 a is a graph depicting the percentage of extended shape change of platelets irradiated with 308 nm of light as compared to broad spectrum light over five days of storage.
  • FIG. 9 b is a graph depicting the expression of P-selectin by platelets irradiated with 308 nm of light as compared to broad spectrum light over five days of storage.
  • FIG. 9 c is a graph depicting the production of lactate by platelets irradiated with 308 nm of light as compared to broad spectrum light over five days of storage.
  • FIG. 9 d is a graph depicting the pH of platelets irradiated with 308 nm of light as compared to broad spectrum light over five days of storage.
  • FIG. 10 is another embodiment of a treatment chamber which may be used in the present invention.
  • FIG. 11 is a graph depicting the spectral data of 320 nm broadband light used with filters.
  • FIG. 12 is a graph depicting the absorption spectrum of hemoglobin and free and bound riboflavin.
  • blood product includes all blood constituents or blood components and therapeutic protein compositions containing proteins derived from blood as described above. Fluids containing biologically active proteins other than those derived from blood may also be treated by the methods and devices of this invention.
  • Photosensitizers of this invention may include compounds which preferentially adsorb to nucleic acids, thus focusing their photodynamic effect upon microorganisms and viruses with little or no effect upon accompanying cells or proteins.
  • Other types of photosensitizers are also useful in this invention, such as those using singlet oxygen-dependent mechanisms.
  • endogenous photosensitizers Most preferred are endogenous photosensitizers.
  • endogenous means naturally found in a human or mammalian body, either as a result of synthesis by the body or by ingestion as an essential foodstuff (e.g. vitamins) or formation of metabolites and/or byproducts in vivo.
  • endogenous photosensitizers are alloxazines such as 7,8-dimethyl-10-ribityl isoalloxazine (riboflavin), 7,8,10-trimethylisoalloxazine (lumiflavin), 7,8-dimethylalloxazine (lumichrome), isoalloxazine-adenine dinucleotide (flavine adenine dinucleotide [FAD]), alloxazine mononucleotide (also known as flavine mononucleotide [FMN] and riboflavine-5-phosphate), vitamin Ks, vitamin L, their metabolites and precursors, and napththoquinones, naphthalenes, naphthols and their derivatives having planar molecular conformations.
  • alloxazines such as 7,8-dimethyl-10-ribityl isoalloxazine (riboflavin), 7,8,10-trimethylisoalloxazine (lumifla
  • alloxazine includes isoalloxazines.
  • Endogenously-based derivative photosensitizers include synthetically derived analogs and homologs of endogenous photosensitizers which may have or lack lower (1-5) alkyl or halogen substituents of the photosensitizers from which they are derived, and which preserve the function and substantial non-toxicity thereof.
  • endogenous photosensitizers particularly when such photosensitizers are not inherently toxic or do not yield toxic photoproducts after photoradiation, no removal or purification step is required after decontamination, and a treated product can be directly returned to a patient's body or administered to a patient in need of its therapeutic effect without any further required processing.
  • Non-endogenous photosensitizers based on endogenous structures such as those described in U.S. Pat. No. 6,268,120, may also be used in the present invention, and is incorporated by reference herein. These non-endogenous photosensitizers and endogenously-based derivative photosentizers may be referred to herein as endogenously-based derivative photosensitizers.
  • RNA ribonucleic acid
  • DNA deoxyribonucleic acid
  • photosensitizers may be used in this invention which have mechanisms of action different from those described for endogenous photosensitizers or endogenously-based derivative photosensitizers.
  • photosensitizers which bind to membranes may also be used.
  • the photosensitizer Upon exposure of the photosensitizer to light of a particular wavelength, the photosensitizer will absorb the light energy, causing photolysis of the photosensitizer and any nucleic acid bound to the photosensitizer.
  • the photosensitizer used in the examples is 7,8-dimethyl-10-ribityl isoalloxazine (riboflavin).
  • Microorganisms or pathogens which may be eradicated or inactivated using pathogen inactivation agents or photosensitizers include, but are not limited to, viruses (both extracellular and intracellular), bacteria, bacteriophages, fungi, blood-transmitted parasites, and protozoa.
  • viruses include acquired immunodeficiency (HIV) virus, hepatitis A, B and C viruses, sinbis virus, cytomegalovirus, vesicular stomatitis virus, herpes simplex viruses, e.g.
  • Bacteriophages include ⁇ X174, ⁇ 6, ⁇ , R17, T 4 , and T 2 .
  • Exemplary bacteria include but are not limited to P. aeruginosa, S. aureus, S. epidermis, L. monocytogenes, E. coli, K. pneumonia and S. marcescens.
  • the fluid to be pathogen inactivated has the photosensitizer added thereto, and the resulting fluid mixture may be exposed to photoradiation of the appropriate peak wavelength and amount to activate the photosensitizer, but less than that which would cause significant non-specific damage to the biological components or substantially interfere with biological activity of other proteins present in the fluid.
  • peak wavelength means that the light is emitted in a narrow range centered around a wavelength having a particular peak intensity.
  • visible light may be centered around a wavelength of approximately 470 nm, and having a maximum intensity at approximately 470 nm.
  • the light may be centered around a narrow range of UV light at an approximate wavelength of 308 nm, and having a maximum intensity at approximately 308 nm.
  • light source or radiation source as defined herein means an emitter of radiant energy, and may include energy in the visible and/or ultraviolet range, as further described below.
  • the photosensitizer may be added directly to the fluid to be pathogen inactivated, or may be flowed into the photopermeable container separately from the fluid being treated, or may be added to the fluid prior to placing the fluid in the photopermeable treatment container.
  • the photosensitizer may also be added to the photopermeable container either before or after sterilization of the treatment container.
  • the fluid containing the photosensitizer may also be flowed into and through a photopermeable container for irradiation, using a flow through type system.
  • the fluid to be treated may be placed in a photopermeable container which is agitated and exposed to photoradiation for a time sufficient to substantially inactivate the microorganisms, in a batch-wise type system.
  • the term “container” refers to a closed or open space, which may be made of rigid or flexible material, e.g., may be a bag or box or trough. In one embodiment, the container may be closed or open at the top and may have openings at both ends, e.g., may be a tube or tubing, to allow for flow-through of fluid therein.
  • a cuvette has been used to exemplify one embodiment of the invention involving a flow-through system.
  • Collection bags such as those used with the Trima® and/or SpectraTM apheresis systems of Gambro, Inc., (f/k/a Cobe Laboratories, Inc., Lakewood, Colo., USA), have been used to exemplify another embodiment involving a batch-wise treatment of the fluid.
  • photopermeable means the material of the treatment container is adequately transparent to photoradiation of the proper wavelength for activating the photosensitizer.
  • the container has a depth (dimension measured in the direction of the radiation from the photoradiation source) sufficient to allow photoradiation to adequately penetrate the container to contact photosensitizer molecules at all distances from the light source and ensure inactivation of pathogens in the fluid to be decontaminated, and a length (dimension in the direction of fluid flow) sufficient to ensure a sufficient exposure time of the fluid to the photoradiation.
  • the materials for making such containers, as well as the depths and lengths of the containers may be easily determined by those skilled in the art, and together with the flow rate of fluid through the container, the intensity of the photoradiation and the absorptivities of the fluid components, e.g., plasma, platelets, red blood cells, will determine the amount of time the fluid should be exposed to photoradiation.
  • the container used may be any container known in the art for holding fluid to be irradiated, including, but not limited to blood bags, cuvettes and tubing.
  • One example, not meant to be limiting which may be used as the container is a Sangewald bag (available from Sengewaldmaschineen GmbH & Co. KG).
  • the blood or blood product may be stored for later delivery to a patient, concentrated, infused directly into a patient or otherwise processed for its ultimate use.
  • FIG. 1 shows in a cross-sectional view, the inside of a radiation or treatment chamber of one type of apparatus that may be used in the present invention.
  • the treatment chamber shown in FIG. 1 may be used in batch-wise systems, however, it should be noted that similar elements may also be used in flow-through systems. It should be noted that throughout the description of the invention, like elements have been given like numerals.
  • the apparatus 55 used for inactivating a fluid which may contain pathogens, consists of an internal chamber 33 having at least one source of radiation 26 . In one preferred embodiment, the internal chamber may contain a second source of radiation 36 . Each radiation source 26 and 36 respectively, is depicted as including a plurality of discrete radiation-emitting elements.
  • the internal chamber 33 further consists of a support platform 25 for supporting the fluid container 10 containing the fluid to be irradiated, and a control unit 11 .
  • Radiation source 26 may be located along the top portion of the internal chamber 33 above the container 10 which holds or contains the fluid to be irradiated, while radiation source 36 may be located along the bottom portion of the internal chamber 33 below the container 10 . Although not shown, radiation sources may also be located along some or all of the sides of the internal chamber 33 perpendicular to the container 10 .
  • the radiation or treatment chamber 55 may alternatively contain a single radiation source at any location within the internal chamber 33 and still comply with the spirit and scope of the present invention.
  • the radiation source including a plurality of radiation-emitting elements collectively designated as source 26 includes an upper support substrate 15 containing a plurality of discrete radiation emitting elements or discrete light sources (see discrete source 20 as one example) mounted thereon.
  • the support substrate 15 may be in an arcuate shape as shown, in a flat shape, or in other configurations which are not shown but are known in the art.
  • the upper support substrate 15 could also be in a shape other than arcuate without departing from the spirit and scope of the invention.
  • the radiation source collectively designated as discrete source 36 includes a lower support substrate 35 which also contains a plurality of discrete radiation emitting elements or discrete light sources (see discrete source 30 as another example).
  • Lower support substrate 35 preferably runs parallel to support platform 25 .
  • the lower support substrate 35 may be substantially flat as shown, or may be in an arcuate shape similar to element 15 above, or may be in a shape other than arcuate, without departing from the spirit and scope of the invention.
  • the support substrates 15 and 35 may include at least one reflective surface, and as shown, may include two or more reflective surfaces 17 and 37 thereon.
  • Reflective surface 17 is shown as running contiguous with upper support substrate 15 .
  • Reflective surface 37 is shown as running contiguous with lower support substrate 35 .
  • the reflective surfaces 17 and 37 may also run contiguously with only a portion of support substrates 15 and 35 .
  • discrete light source devices 20 and 30 extend outwardly away from the surface of the support substrates 15 and 35 .
  • a discrete light source could be recessed into the surface such that the surface surrounds each discrete light source in a parabolic shape (not shown).
  • the support substrate may or may not have reflective surfaces.
  • the reflective surface may not contain any light sources.
  • a reflective surface containing no light sources may be located within the treatment chamber on a side opposite from the radiation source.
  • the support platform 25 may have a reflective surface 39 .
  • This reflective surface 39 on support platform 25 may be in place of, or may be in addition to another reflective surface (see element 17 as one example) within the treatment chamber. There may also be no reflective surfaces at all within the treatment chamber.
  • the reflective surface may be coated with a highly reflective material which serves to reflect the radiation emitted from the lights back and forth throughout the treatment chamber until the radiation is preferably completely absorbed by the fluid being irradiated.
  • the highly reflective nature of the reflective surface reflects the emitted light back at the fluid-filled bag or container 10 with minimum reduction in the light intensity.
  • support platform 25 is positioned within the internal treatment chamber 33 .
  • the support platform 25 may be located substantially in the center of the radiation or treatment chamber (as shown in FIG. 1 ), or may be located closer to either the top portion or the bottom portion of the treatment chamber without departing from the spirit and scope of the present invention.
  • the support platform 25 supports the container 10 containing the fluid to be irradiated.
  • the support platform 25 may also be defined as a tray or a shelf.
  • the platform 25 may be made of a photopermeable material to enable radiation emitted by the lights to be transmitted through the platform and penetrate the fluid contained within the container 10 .
  • the platform may also be a wire or other similar mesh-like material to allow maximum light transmissivity therethrough.
  • the support platform 25 is preferably capable of movement in multiple directions within the treatment chamber.
  • One type of agitator such as a Helmer flatbed agitation system available from Helmer Corp. (Noblesville, Ind., USA) may be used. This type of agitator provides to and fro motion. Other types of agitators may also be used to provide a range of motion to the fluid contained within the container 10 , without departing from the spirit and scope of the invention.
  • the support platform might be oriented in a vertical direction and the light sources may be rotated about a horizontal axis.
  • the support platform 25 may alternatively rotate in multiple possible directions within the radiation chamber in varying degrees from between 0° to 360°. Support platform 25 may also oscillate back and forth, or side to side along the same plane.
  • one or more of the light sources may also move in a coordinated manner with the movement of the support platform. Such oscillation or rotation would enable the majority of the photosensitizer and fluid contained within the container 10 to be exposed to the light emitted from each of the discrete radiation sources (e.g. discrete sources 20 and 30 ), by continually replacing the exposed fluid at the light-fluid interface with fluid from other parts of the bag not yet exposed to the light. Such mixing continually brings to the surface new fluid to be exposed to light.
  • control unit 11 The movement of both the support platform 25 and/or the radiation sources 26 and 36 may be controlled by control unit 11 .
  • the control unit 11 may also control the rate of light emission.
  • each discrete light source 20 and 30 emits a peak wavelength of light to irradiate the fluid contained in bag 10 .
  • the peak wavelength of light emitted by each discrete light source is selected to provide irradiation of a sufficient intensity to activate both the photosensitizer in a pathogen inactivation process as well as to provide sufficient penetration of light into the particular fluid being irradiated, without causing significant damage to the blood or blood components being irradiated.
  • the preferred photosensitizer is riboflavin. To irradiate a fluid containing red blood cells and riboflavin, it is preferred that each discrete light source 20 and 30 be selected to emit light at a peak wavelength of 470 nm.
  • the 470 nm of light used in this invention is close to the optimal wavelength of light to both photolyse riboflavin, and also to enable significant penetration of the fluid containing red blood cells by the light.
  • FIG. 3 shows the absorption spectrum of riboflavin.
  • riboflavin is best photolysed at an absorption peak of approximately 450 nm.
  • the absorption spectrum also shows that riboflavin may be successfully photolysed at an absorption peak of approximately 370 nm.
  • a peak wavelength of 370 nm may be used as long as there is minimal absorption by red blood cells and no significant damage to the red blood cells caused by the absorbed light.
  • FIG. 4 shows the absorption spectrum of hemoglobin at various concentrations. As shown, all concentrations of hemoglobin have absorption peaks around 419 nm. As seen from FIG. 4 , a wavelength of 419 nm will be completely absorbed by the red blood cells, significantly decreasing penetration of the light through the cells into the surrounding fluid. At this wavelength, no light will be available to photolyze riboflavin, and therefore, any pathogens contained in the red blood cells will not be reduced. At a wavelength of approximately 470 nm, riboflavin has an absorption peak and the red blood cells will not absorb the light, allowing riboflavin to be photolyzed. This can be seen in the combined absorption peaks of FIGS. 3 and 4 , as shown in FIG.
  • a wavelength of 470 nm will not be completely absorbed by red blood cells, and will therefore be able to penetrate into the fluid containing red blood cells.
  • a wavelength of approximately 470 nm will photolyse riboflavin, thus enabling pathogen reduction by riboflavin in red blood cells.
  • light having a peak wavelength of around 308 nm may also be used.
  • the range of light between 305-313 nm, and having a peak intensity at around 308 nm when used to irradiate a fluid with a photosensitizer appears to give adequate virus kill and does not produce large scale protein damage to platelets.
  • 308 nm of light also appears to prevent platelet aggregation.
  • each radiation source 26 may consist of a bank or array of a plurality of discrete LEDs devices.
  • LED devices 20 , 21 and 22 are self-contained emitters of radiation. Each LED emits a single color of light when an electrical current is applied.
  • Each of the LED devices in the array 26 may also emit light in the same peak wavelength, which for red blood cells is preferably selected to be around approximately 470 nm, and for platelets is preferably selected to be around approximately 308 nm.
  • the discrete radiation sources or lights may be arranged in banks or arrays containing multiple rows of individual lights, or may be arranged in a single row (not shown). As shown in FIG. 5 , if LED devices are used, a plurality of discrete LED devices may be arranged in multiple rows. The lights may also be staggered or offset from each other (not shown). If a bank or an array of LED lights is located in both the top and the bottom of the irradiation chamber 55 (see FIG. 1 ), or in a vertical orientation as described above, each bag or container 10 containing fluid to be irradiated will be exposed to light on both the top and the bottom surfaces (or on both sides of the bag if in a vertical orientation). A reflective surface 17 (like that shown in FIG. 1 ) may also be part of the array.
  • One or more light sources may be used in the irradiation apparatus, depending on the output required to substantially inactivate viruses which may be present in the blood product, and without substantially damaging the blood component being irradiated.
  • the lights used in this invention may be LED devices or other narrow bandwidth sources such as excimer light sources. LEDs are advantageous because they emit light in a very narrow spectrum. Emitting light in a narrow spectrum may be beneficial to the blood product being irradiated because all non-useful wavelengths of light which might damage the blood or blood component being irradiated are eliminated. LED devices are available from any one of a number of companies. Some companies that manufacture LED devices useful in this invention are Cree, Inc. (Durham, N.C., USA); Nichia, Co. (Tokushima, JP); Kingbright, Corp. (City of Industry, Calif., USA) and Lumileds Lighting, LLC (San Jose, Calif., USA).
  • LEDs which emit light in the blue color spectrum and emit light at a peak wavelength of approximately 470 nm are most preferred for inactivating pathogens that may be contained in red blood cells.
  • Excimer light sources or LEDs which emit light at a peak wavelength of approximately 308 nm are most preferred for irradiating pathogens that may be contained in platelets and/or plasma.
  • One type of excimer light source which may be used in the present invention are lights which emit at a peak wavelength of 308 nm (available from Ushio Corp.). As can be seen from the light spectrum shown in FIG. 6 , the Ushio bulbs have a peak wavelength at approximately 308 nm, as compared to 320 nm broadband fluorescent bulbs, which generate light over a much wider spectrum. It should be noted that although Ushio bulbs are described, any light bulbs which emit light at a peak wavelength of 308 nm may be used.
  • One Ushio bulb produces a flux of around 0.04 J/cm 2 /min while two bulbs provide a flux of around 0.11 J/cm 2 /min. This is compared to the full output of 320 nm fluorescent bulbs which produce a flux of around 0.45 J/cm 2 /min.
  • To irradiate platelets at an energy level of 7 J/cm 2 one Ushio bulb requires 175 minutes of irradiation, while two bulbs require 64 minutes of irradiation. Three Ushio bulbs require irradiation for 24.1 minutes, while four Ushio bulbs require 14 minutes of irradiation. Two banks of four bulbs of broad spectrum 320 nm fluorescent bulbs require 15.5 minutes.
  • long pass (LP) filters were initially employed.
  • the spectral data of broad spectrum 320 nm lights which were subjected to filters which filter out light below a certain wavelength are shown in FIG. 11 .
  • a 305 LP filter when applied to light from a 320 nm broadband source will filter out wavelengths below 305 nm.
  • a 320 LP filter will filter out wavelengths below 320 nm.
  • a 295 LP filter will filter out wavelengths below 295 nm.
  • light at wavelengths of 320 nm or above provide poorer viral kill as compared to light at wavelengths below 320.
  • FIG. 8 shows that provides poorer viral kill as compared to light at wavelengths below 320.
  • FIG. 8 also demonstrates that light emitted in a very narrow range around 313 nm may also be used to substantially reduce pathogens in both plasma and platelets. This graph shows that in plasma (and by analogy in platelets), the amount of virus kill tracks with a given energy dose. Furthermore, light in the 313 nm range appears to follow the amount of viral kill produced by light in the lower range (308 nm).
  • FIG. 7 is a graph comparing BVDV inactivation in plasma as a function of energy.
  • the conditions used to substantially reduce virus in plasma are analogous to the conditions used to substantially reduce virus in platelets.
  • BVDV was spiked into a 278 mL solution containing 90% plasma carryover.
  • Riboflavin was added at a concentration of between 30-50 ⁇ M.
  • Virus kill achieved using a broadband source of light having a peak wavelength of 320 nm was compared to kill achieved using a narrow bandwidth source with a peak wavelength of 308 nm and kill achieved using a broad spectrum of 320 nm light. As shown, light emitting peaks at 308 nm provided substantially the same amount of viral kill as light emitted from a broad spectrum 320 nm light source, indicating that 308 nm light is very efficient at kill.
  • FIG. 9 a is a graph of the percentage of extended shape change of platelets over five days of storage.
  • Extended shape change is a measure of platelets ability to respond to agonists. Irradiation of platelets with 308 nm Ushio bulbs appears to maintain a higher percentage of ESC as compared to platelets irradiated with broad spectrum 320 nm bulbs.
  • FIG. 9 b is a graph showing P-selectin expression as a function of time.
  • P-selectin is a marker which appears on the surface of platelets when platelets are in an activated state. Platelets which are activated are more likely to aggregate together than non-activated platelets. The occurrence of aggregation has been correlated with removal of platelets from the circulation system and hence have short survival times in the body of a recipient when treated platelets are infused. It appears from FIG. 9 b that irradiation using broad spectrum light causes platelets to become more activated than platelets irradiated with light at a peak wavelength of 308 nm.
  • FIG. 9 c shows the production of lactate by platelets during storage. It has been observed that irradiated platelets have suppressed mitochondrial function. If the mitochondria of platelets is suppressed by UV light, platelets are unable to create ATP (cellular energy) through aerobic respiration. If platelets are unable to create energy through aerobic respiration, they will create energy through an alternative pathway called the glycolysis pathway. One metabolite produced by the glycolysis pathway is lactate or lactic acid. Lactic acid buildup within cells causes the pH of the solution to drop. Such a drop in pH causes decreased cell quality during storage. As shown in FIG. 9 c , platelets irradiated with broad spectrum light produced lactate at a much higher rate than platelets irradiated with light at a peak wavelength of 308 nm.
  • FIG. 9 d is a graph measuring the drop in pH of irradiated platelets over the course of five days. Drops in the pH of platelets during storage is indicative of a decrease in the quality of stored platelets. Platelets which were irradiated with broad spectrum light suffered a greater drop in pH over five days of storage than did platelets irradiated with light at 308 nm.
  • Ushio bulbs are given as one example of bulbs which could be used in the present invention, it should be noted that any type of bulbs, either fluorescent or LEDs which emit light at a peak wavelength between 305-313 nm may be used. Filters which filter out undesired wavelengths of light may also be used to obtain the desired peak wavelength.
  • the light sources 20 and 30 may be pulsed. Pulsing the light may be advantageous because the intensity of light produced by the light sources may be increased dramatically if the lights are allowed to be turned off and rested between light pulses. Pulsing the light at a high intensity also allows for greater depth of light penetration into the fluid being irradiated, thus allowing a thicker layer of fluid to be irradiated with each light pulse.
  • FIG. 10 shows an alternative embodiment of an irradiation or treatment chamber to be used with the present invention.
  • a bank of light sources 50 which emit peak wavelengths of light and which may or may not be capable of being pulsed, may be located within the top of the irradiation chamber extending from lid 40 .
  • a bank of lights may also be located in the bottom of the irradiation chamber as well.
  • a reflective surface 57 is shown as part of the inner surface of lid 40 , however, reflective surface 57 or another one or more surfaces (not shown) may be located anywhere within the radiation chamber as introduced above.
  • the lid 40 is capable of being opened and closed. During exposure of the bag 10 containing the fluid to be irradiated to the light sources, the lid 40 is in a closed position (not shown). To add or remove the bag 10 containing the fluid to be irradiated from the irradiation chamber, a drawer 45 located on the front of the irradiation chamber may be disposed in an open position (as shown). During the irradiation procedure, the drawer 45 is placed in a closed position (not shown).
  • the light sources 50 as shown in FIG. 10 may be fluorescent or incandescent tubes, which stretch the length of the irradiation chamber, or may be a single light source which extends the length and width of the entire chamber (not shown).
  • the LEDs shown in FIG. 5 may also be used in this embodiment.
  • the support platform 67 may be located within and/or forming part of drawer 45 .
  • the support platform 67 may contain gaps 60 or holes or spaces within the platform 67 to allow radiation to penetrate through the gaps directly into the container 10 containing fluid to be irradiated.
  • a cooling system may also optionally be included. As shown in FIG. 10 , air cooling using at least one fan 65 may be preferred but it is understood that other well-known systems can also be used. Although not shown in FIG. 10 , the method may also include the use of temperature sensors and other cooling mechanisms where necessary to keep the temperature below temperatures at which desired proteins and blood components in the fluid being irradiated are damaged. Preferably, the temperature is kept between about 0° C. and about 45° C., more preferably between about 4° C. and about 37° C, and most preferably about 28° C.
  • peak wavelengths of light may be used to irradiate blood or blood components in a flow-through irradiation system as well, without departing from the scope of the present invention.

Abstract

Methods and apparatuses are provided for inactivation of pathogens in fluids containing blood products. Preferred methods include the steps of adding an effective, non-toxic amount of a photosensitizer such as riboflavin to the blood product and exposing the fluid to light having a peak wavelength.

Description

  • This application is a Continuation of U.S. application Ser. No. 10/357,599, filed Feb. 3, 2003, which is a Continuation-In-Part of U.S. application Ser. No. 09/962,029 filed Sep. 25, 2001, which is a Continuation-In-Part of U.S. application Ser. No. 09/596,429 filed Jun. 15, 2000. Application Ser. No. 09/962,029 claims benefit of U.S. Provisional Application 60/235,999 filed Sep. 27, 2000. This Application also claims the benefit of U.S. Provisional Application No. 60/353,233 filed Feb. 1, 2002.
  • BACKGROUND
  • Contamination of whole blood or blood products with infectious microorganisms such as HIV, hepatitis and other viruses and bacteria present a serious health hazard for those who must receive transfusions of whole blood or administration of various blood products or blood components such as platelets, red cells, blood plasma, Factor VIII, plasminogen, fibronectin, anti-thrombin III, cryoprecipitate, human plasma protein fraction, albumin, immune serum globulin, prothrombin complex plasma growth hormones, and other components isolated from blood. Blood screening procedures may miss pathogenic contaminants, and sterilization procedures which do not damage cellular blood components but effectively inactivate all infectious viruses and other microorganisms have not heretofore been available.
  • The use of pathogen inactivating agents include certain photosensitizers, or compounds which absorb light of defined wavelengths and transfer the absorbed energy to an energy acceptor, have been proposed for inactivation of microorganisms found in blood products or fluids containing blood products. Such photosensitizers may be added to the fluid containing blood or blood products and irradiated.
  • The photosensitizers which may be used in this invention include any photosensitizers known to the art to be useful for inactivating microorganisms. A “photosensitizer” is defined as any compound which absorbs radiation at one or more defined wavelengths and subsequently utilizes the absorbed energy to carry out a chemical process. Examples of photosensitizers which may be used for the reduction of pathogens in blood or blood products include porphyrins, psoralens, dyes such as neutral red, methylene blue, acridine, toluidines, flavine (acriflavine hydrochloride) and phenothiazine derivatives, coumarins, quinolones, quinones, and anthroquinones.
  • A number of systems and methods for irradiating pathogens in a fluid with light either with or without the addition of a photosensitizer are known in the art. For example, U.S. Pat. No. 5,762,867 is directed toward a system for activating a photoactive agent present in a body fluid with light emitting diodes (LEDs).
  • U.S. Pat. No. 5,527,704 is directed toward an apparatus containing LEDs used to activate a fluid containing methylene blue.
  • U.S. Pat. No. 5,868,695 discloses using LEDs having a red color and emitting light at a wavelength of 690 nm in combination with benzoporphrin derivative photosensitizers to inactivate red blood cells. As taught in this patent, at a wavelength of 690 nm, red blood cells are essentially transparent to radiation, and as such, the benzoporphorin derivatives absorb radiation at this wavelength to become activated. Also disclosed in this patent is the use of LEDs having a blue color and emitting light at a peak wavelength of 425 nm to inactivate platelets.
  • U.S. Pat. No. 5,658,722 discloses irradiating platelets using UVA1 light having an emission peak near 365 nm. This patent teaches that damage to platelets is caused by short UVA <345 nm, and unlike the present invention, calls for removing UVA wavelengths below 345 nm.
  • Use of light which is variably pulsed at a wavelength of 308 nm without the addition of a photosensitizer to inactivate virus in a washed platelet product is taught in an article by Prodouz et al. (Use of Laser-UV for Inactivation of Virus in Blood Products; Kristina Prodouz, Joseph Fratantoni, Elizabeth Boone and Robert Bonner; Blood, Vol 70, No. 2). This article does not teach or suggest the addition of a photosensitizer in combination with light to kill viruses.
  • The present invention is directed toward the reduction of pathogens which may be present in blood or blood products using light having peak wavelengths in combination with an endogenous photosensitizer.
  • SUMMARY
  • The present invention provides a method and apparatus for irradiating a fluid containing blood products and pathogens, together with a photoactive agent. The fluid is exposed to light having a peak wavelength which is chosen to activate both the photoactive agent as well as to penetrate the fluid containing the specific blood product to inactivate any pathogens contained in the fluid.
  • One embodiment useful with the methods of the present invention is a radiation or treatment chamber having includes a bank or banks or arrays of lights, which emit light at an approximate peak wavelength of 470 nm, which is suitable for irradiating a red blood cell product.
  • Another embodiment of the present invention includes use of light emitted at an approximate peak wavelength of 308 nm, which is suitable for irradiating a platelet or plasma product.
  • A radiation enhancer such as a second radiation source or a reflective surface may be included in the radiation or treatment chamber. The radiation enhancer may be placed adjacent to the container containing the fluid to be irradiated or opposite the radiation source to increase the amount of radiation contacting the fluid within the container.
  • The radiation or treatment chamber may also preferably include a means for producing movement in the fluid to be irradiated. Movement provides many benefits including improvement of the efficiency of the irradiation process by helping mix the photosensitizer with the fluid to be pathogen inactivated to provide turnover of the fluid within the container at the container-light interface.
  • Positioning the fluid to be irradiated so that it receives energy of sufficient wavelength and power to reduce pathogens contained in the fluid may include a support platform, a shelf or a tray for the sample to be disposed upon; an opening or gap between two supports which may be a light or light arrays, where the fluid within the container is positioned between the supports; or other means known in the art. The support platform may move in a substantially horizontal manner as in a conveyer line, or may oscillate or agitate. A support platform which may move in a substantially vertical plane or any angle therebetween may also be used. The fluid-holding support platform or surface may be transparent to one or more of the wavelengths of light applied. The fluid within the container may also be placed on the support surface between two or more sources of radiation, in a sandwich-like configuration.
  • Alternative sources of radiation may be used, depending on a variety of factors, including, but not limited to the type of fluid being irradiated and the type of photosensitizer being used.
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a cross-sectional view of a treatment chamber which may be used in the present invention.
  • FIG. 2 is a cross-sectional view of a treatment chamber like that of FIG. 1, but with an alternative reflective surface that may also be used in the present invention.
  • FIG. 3 is a graph depicting the absorption spectrum of riboflavin.
  • FIG. 4 is a graph depicting the absorption spectrum of hemoglobin at various concentrations.
  • FIG. 5 is a plan view of an array of LEDs that may be used in the present invention.
  • FIG. 6 is a graph depicting the light spectrum of one type of fluorescent bulb which may be used in the present invention as compared to a broad band type of bulb.
  • FIG. 7 is a graph comparing virus inactivation as a function of energy.
  • FIG. 8 is another graph comparing virus inactivation as a function of energy.
  • FIG. 9 a is a graph depicting the percentage of extended shape change of platelets irradiated with 308 nm of light as compared to broad spectrum light over five days of storage.
  • FIG. 9 b is a graph depicting the expression of P-selectin by platelets irradiated with 308 nm of light as compared to broad spectrum light over five days of storage.
  • FIG. 9 c is a graph depicting the production of lactate by platelets irradiated with 308 nm of light as compared to broad spectrum light over five days of storage.
  • FIG. 9 d is a graph depicting the pH of platelets irradiated with 308 nm of light as compared to broad spectrum light over five days of storage.
  • FIG. 10 is another embodiment of a treatment chamber which may be used in the present invention.
  • FIG. 11 is a graph depicting the spectral data of 320 nm broadband light used with filters.
  • FIG. 12 is a graph depicting the absorption spectrum of hemoglobin and free and bound riboflavin.
  • DETAILED DESCRIPTION
  • The term “blood product” as used herein includes all blood constituents or blood components and therapeutic protein compositions containing proteins derived from blood as described above. Fluids containing biologically active proteins other than those derived from blood may also be treated by the methods and devices of this invention.
  • Photosensitizers of this invention may include compounds which preferentially adsorb to nucleic acids, thus focusing their photodynamic effect upon microorganisms and viruses with little or no effect upon accompanying cells or proteins. Other types of photosensitizers are also useful in this invention, such as those using singlet oxygen-dependent mechanisms.
  • Most preferred are endogenous photosensitizers. The term “endogenous” means naturally found in a human or mammalian body, either as a result of synthesis by the body or by ingestion as an essential foodstuff (e.g. vitamins) or formation of metabolites and/or byproducts in vivo. Examples of such endogenous photosensitizers are alloxazines such as 7,8-dimethyl-10-ribityl isoalloxazine (riboflavin), 7,8,10-trimethylisoalloxazine (lumiflavin), 7,8-dimethylalloxazine (lumichrome), isoalloxazine-adenine dinucleotide (flavine adenine dinucleotide [FAD]), alloxazine mononucleotide (also known as flavine mononucleotide [FMN] and riboflavine-5-phosphate), vitamin Ks, vitamin L, their metabolites and precursors, and napththoquinones, naphthalenes, naphthols and their derivatives having planar molecular conformations. The term “alloxazine” includes isoalloxazines. Endogenously-based derivative photosensitizers include synthetically derived analogs and homologs of endogenous photosensitizers which may have or lack lower (1-5) alkyl or halogen substituents of the photosensitizers from which they are derived, and which preserve the function and substantial non-toxicity thereof. When endogenous photosensitizers are used, particularly when such photosensitizers are not inherently toxic or do not yield toxic photoproducts after photoradiation, no removal or purification step is required after decontamination, and a treated product can be directly returned to a patient's body or administered to a patient in need of its therapeutic effect without any further required processing. Using endogenous photosensitizers to inactivate pathogens in a blood product are described in U.S. Pat. No. 6,258,577 and No. 6,277,337, herein incorporated by reference in their entirety to the amount not inconsistent.
  • Non-endogenous photosensitizers based on endogenous structures, such as those described in U.S. Pat. No. 6,268,120, may also be used in the present invention, and is incorporated by reference herein. These non-endogenous photosensitizers and endogenously-based derivative photosentizers may be referred to herein as endogenously-based derivative photosensitizers.
  • One mechanism by which these photosensitizers may inactivate pathogens is by interfering with nucleic acids, so as to prevent replication of the nucleic acid. As used herein, the term “inactivation of a pathogen” means totally or partially preventing the pathogen from replicating, either by killing the pathogen or otherwise interfering with its ability to reproduce. Specificity of action of the preferred photosensitizer is conferred by the close proximity of the photosensitizer to the nucleic acid of the pathogen and this may result from binding of the photosensitizer to the nucleic acid. “Nucleic acid” includes ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). It should be noted however, photosensitizers may be used in this invention which have mechanisms of action different from those described for endogenous photosensitizers or endogenously-based derivative photosensitizers. For example, photosensitizers which bind to membranes may also be used.
  • Upon exposure of the photosensitizer to light of a particular wavelength, the photosensitizer will absorb the light energy, causing photolysis of the photosensitizer and any nucleic acid bound to the photosensitizer. In this invention, the photosensitizer used in the examples is 7,8-dimethyl-10-ribityl isoalloxazine (riboflavin).
  • Microorganisms or pathogens which may be eradicated or inactivated using pathogen inactivation agents or photosensitizers include, but are not limited to, viruses (both extracellular and intracellular), bacteria, bacteriophages, fungi, blood-transmitted parasites, and protozoa. Exemplary viruses include acquired immunodeficiency (HIV) virus, hepatitis A, B and C viruses, sinbis virus, cytomegalovirus, vesicular stomatitis virus, herpes simplex viruses, e.g. types I and II, human T-lymphotropic retroviruses, HTLV-III, lymphadenopathy virus LAV/IDAV, parvovirus, transfusion-transmitted (TT) virus, Epstein-Barr virus, and others known to the art. Bacteriophages include Φ X174, Φ 6, λ, R17, T4, and T2. Exemplary bacteria include but are not limited to P. aeruginosa, S. aureus, S. epidermis, L. monocytogenes, E. coli, K. pneumonia and S. marcescens.
  • The fluid to be pathogen inactivated has the photosensitizer added thereto, and the resulting fluid mixture may be exposed to photoradiation of the appropriate peak wavelength and amount to activate the photosensitizer, but less than that which would cause significant non-specific damage to the biological components or substantially interfere with biological activity of other proteins present in the fluid.
  • The term peak wavelength as defined herein means that the light is emitted in a narrow range centered around a wavelength having a particular peak intensity. In one embodiment, visible light may be centered around a wavelength of approximately 470 nm, and having a maximum intensity at approximately 470 nm. In another embodiment, the light may be centered around a narrow range of UV light at an approximate wavelength of 308 nm, and having a maximum intensity at approximately 308 nm. The term light source or radiation source as defined herein means an emitter of radiant energy, and may include energy in the visible and/or ultraviolet range, as further described below.
  • The photosensitizer may be added directly to the fluid to be pathogen inactivated, or may be flowed into the photopermeable container separately from the fluid being treated, or may be added to the fluid prior to placing the fluid in the photopermeable treatment container. The photosensitizer may also be added to the photopermeable container either before or after sterilization of the treatment container.
  • The fluid containing the photosensitizer may also be flowed into and through a photopermeable container for irradiation, using a flow through type system. Alternatively, the fluid to be treated may be placed in a photopermeable container which is agitated and exposed to photoradiation for a time sufficient to substantially inactivate the microorganisms, in a batch-wise type system.
  • The term “container” refers to a closed or open space, which may be made of rigid or flexible material, e.g., may be a bag or box or trough. In one embodiment, the container may be closed or open at the top and may have openings at both ends, e.g., may be a tube or tubing, to allow for flow-through of fluid therein. A cuvette has been used to exemplify one embodiment of the invention involving a flow-through system. Collection bags, such as those used with the Trima® and/or Spectra™ apheresis systems of Gambro, Inc., (f/k/a Cobe Laboratories, Inc., Lakewood, Colo., USA), have been used to exemplify another embodiment involving a batch-wise treatment of the fluid.
  • The term “photopermeable” means the material of the treatment container is adequately transparent to photoradiation of the proper wavelength for activating the photosensitizer. In a flow-through system, the container has a depth (dimension measured in the direction of the radiation from the photoradiation source) sufficient to allow photoradiation to adequately penetrate the container to contact photosensitizer molecules at all distances from the light source and ensure inactivation of pathogens in the fluid to be decontaminated, and a length (dimension in the direction of fluid flow) sufficient to ensure a sufficient exposure time of the fluid to the photoradiation. The materials for making such containers, as well as the depths and lengths of the containers may be easily determined by those skilled in the art, and together with the flow rate of fluid through the container, the intensity of the photoradiation and the absorptivities of the fluid components, e.g., plasma, platelets, red blood cells, will determine the amount of time the fluid should be exposed to photoradiation. The container used may be any container known in the art for holding fluid to be irradiated, including, but not limited to blood bags, cuvettes and tubing. One example, not meant to be limiting which may be used as the container is a Sangewald bag (available from Sengewald Verpackungen GmbH & Co. KG).
  • After treatment, the blood or blood product may be stored for later delivery to a patient, concentrated, infused directly into a patient or otherwise processed for its ultimate use.
  • FIG. 1 shows in a cross-sectional view, the inside of a radiation or treatment chamber of one type of apparatus that may be used in the present invention. The treatment chamber shown in FIG. 1 may be used in batch-wise systems, however, it should be noted that similar elements may also be used in flow-through systems. It should be noted that throughout the description of the invention, like elements have been given like numerals. The apparatus 55, used for inactivating a fluid which may contain pathogens, consists of an internal chamber 33 having at least one source of radiation 26. In one preferred embodiment, the internal chamber may contain a second source of radiation 36. Each radiation source 26 and 36 respectively, is depicted as including a plurality of discrete radiation-emitting elements. The internal chamber 33 further consists of a support platform 25 for supporting the fluid container 10 containing the fluid to be irradiated, and a control unit 11.
  • As introduced above, two sources of radiation are shown within internal chamber 33. Radiation source 26 may be located along the top portion of the internal chamber 33 above the container 10 which holds or contains the fluid to be irradiated, while radiation source 36 may be located along the bottom portion of the internal chamber 33 below the container 10. Although not shown, radiation sources may also be located along some or all of the sides of the internal chamber 33 perpendicular to the container 10. The radiation or treatment chamber 55 may alternatively contain a single radiation source at any location within the internal chamber 33 and still comply with the spirit and scope of the present invention.
  • The radiation source including a plurality of radiation-emitting elements collectively designated as source 26 includes an upper support substrate 15 containing a plurality of discrete radiation emitting elements or discrete light sources (see discrete source 20 as one example) mounted thereon. The support substrate 15 may be in an arcuate shape as shown, in a flat shape, or in other configurations which are not shown but are known in the art. Thus, the upper support substrate 15 could also be in a shape other than arcuate without departing from the spirit and scope of the invention.
  • As further depicted in FIG. 1, the radiation source collectively designated as discrete source 36 includes a lower support substrate 35 which also contains a plurality of discrete radiation emitting elements or discrete light sources (see discrete source 30 as another example). Lower support substrate 35 preferably runs parallel to support platform 25. The lower support substrate 35 may be substantially flat as shown, or may be in an arcuate shape similar to element 15 above, or may be in a shape other than arcuate, without departing from the spirit and scope of the invention.
  • As shown in FIG. 1, the support substrates 15 and 35 may include at least one reflective surface, and as shown, may include two or more reflective surfaces 17 and 37 thereon. Reflective surface 17 is shown as running contiguous with upper support substrate 15. Reflective surface 37 is shown as running contiguous with lower support substrate 35. The reflective surfaces 17 and 37 may also run contiguously with only a portion of support substrates 15 and 35. As shown in FIG. 1, discrete light source devices 20 and 30 extend outwardly away from the surface of the support substrates 15 and 35. Alternatively, a discrete light source could be recessed into the surface such that the surface surrounds each discrete light source in a parabolic shape (not shown). The support substrate may or may not have reflective surfaces. In a further alternative configuration, the reflective surface may not contain any light sources. Such a reflective surface containing no light sources (not shown) may be located within the treatment chamber on a side opposite from the radiation source. As shown in FIG. 2, the support platform 25 may have a reflective surface 39. This reflective surface 39 on support platform 25 may be in place of, or may be in addition to another reflective surface (see element 17 as one example) within the treatment chamber. There may also be no reflective surfaces at all within the treatment chamber.
  • In any of these reflective surface embodiments, the reflective surface may be coated with a highly reflective material which serves to reflect the radiation emitted from the lights back and forth throughout the treatment chamber until the radiation is preferably completely absorbed by the fluid being irradiated. The highly reflective nature of the reflective surface reflects the emitted light back at the fluid-filled bag or container 10 with minimum reduction in the light intensity.
  • In FIG. 1, support platform 25 is positioned within the internal treatment chamber 33. The support platform 25 may be located substantially in the center of the radiation or treatment chamber (as shown in FIG. 1), or may be located closer to either the top portion or the bottom portion of the treatment chamber without departing from the spirit and scope of the present invention. The support platform 25 supports the container 10 containing the fluid to be irradiated. The support platform 25 may also be defined as a tray or a shelf. Additionally or alternatively, the platform 25 may be made of a photopermeable material to enable radiation emitted by the lights to be transmitted through the platform and penetrate the fluid contained within the container 10. The platform may also be a wire or other similar mesh-like material to allow maximum light transmissivity therethrough.
  • The support platform 25 is preferably capable of movement in multiple directions within the treatment chamber. One type of agitator, such as a Helmer flatbed agitation system available from Helmer Corp. (Noblesville, Ind., USA) may be used. This type of agitator provides to and fro motion. Other types of agitators may also be used to provide a range of motion to the fluid contained within the container 10, without departing from the spirit and scope of the invention. For example, the support platform might be oriented in a vertical direction and the light sources may be rotated about a horizontal axis. The support platform 25 may alternatively rotate in multiple possible directions within the radiation chamber in varying degrees from between 0° to 360°. Support platform 25 may also oscillate back and forth, or side to side along the same plane. As a further alternative, one or more of the light sources may also move in a coordinated manner with the movement of the support platform. Such oscillation or rotation would enable the majority of the photosensitizer and fluid contained within the container 10 to be exposed to the light emitted from each of the discrete radiation sources (e.g. discrete sources 20 and 30), by continually replacing the exposed fluid at the light-fluid interface with fluid from other parts of the bag not yet exposed to the light. Such mixing continually brings to the surface new fluid to be exposed to light.
  • The movement of both the support platform 25 and/or the radiation sources 26 and 36 may be controlled by control unit 11. The control unit 11 may also control the rate of light emission.
  • In a preferred embodiment each discrete light source 20 and 30 emits a peak wavelength of light to irradiate the fluid contained in bag 10. The peak wavelength of light emitted by each discrete light source is selected to provide irradiation of a sufficient intensity to activate both the photosensitizer in a pathogen inactivation process as well as to provide sufficient penetration of light into the particular fluid being irradiated, without causing significant damage to the blood or blood components being irradiated. The preferred photosensitizer is riboflavin. To irradiate a fluid containing red blood cells and riboflavin, it is preferred that each discrete light source 20 and 30 be selected to emit light at a peak wavelength of 470 nm. The 470 nm of light used in this invention is close to the optimal wavelength of light to both photolyse riboflavin, and also to enable significant penetration of the fluid containing red blood cells by the light.
  • FIG. 3 shows the absorption spectrum of riboflavin. As is seen in FIG. 3, riboflavin is best photolysed at an absorption peak of approximately 450 nm. The absorption spectrum also shows that riboflavin may be successfully photolysed at an absorption peak of approximately 370 nm. A peak wavelength of 370 nm may be used as long as there is minimal absorption by red blood cells and no significant damage to the red blood cells caused by the absorbed light.
  • FIG. 4 shows the absorption spectrum of hemoglobin at various concentrations. As shown, all concentrations of hemoglobin have absorption peaks around 419 nm. As seen from FIG. 4, a wavelength of 419 nm will be completely absorbed by the red blood cells, significantly decreasing penetration of the light through the cells into the surrounding fluid. At this wavelength, no light will be available to photolyze riboflavin, and therefore, any pathogens contained in the red blood cells will not be reduced. At a wavelength of approximately 470 nm, riboflavin has an absorption peak and the red blood cells will not absorb the light, allowing riboflavin to be photolyzed. This can be seen in the combined absorption peaks of FIGS. 3 and 4, as shown in FIG. 12. As can be seen in FIG. 4 and FIG. 12, a wavelength of 470 nm will not be completely absorbed by red blood cells, and will therefore be able to penetrate into the fluid containing red blood cells. As is seen in FIG. 3 and FIG. 12, a wavelength of approximately 470 nm will photolyse riboflavin, thus enabling pathogen reduction by riboflavin in red blood cells. Such results are unexpected, because as is taught by U.S. Pat. No. 5,527,704, to inactivate fluid containing red blood cells requires light at a wavelength of 690 nm, because red blood cells are transparent to light at this wavelength.
  • To inactivate pathogens contained in fluid which may contain platelets and/or plasma with a photosensitizer, light having a peak wavelength of around 308 nm may also be used. The range of light between 305-313 nm, and having a peak intensity at around 308 nm when used to irradiate a fluid with a photosensitizer appears to give adequate virus kill and does not produce large scale protein damage to platelets. 308 nm of light also appears to prevent platelet aggregation.
  • As shown in FIG. 5, each radiation source 26 may consist of a bank or array of a plurality of discrete LEDs devices. LED devices 20, 21 and 22 are self-contained emitters of radiation. Each LED emits a single color of light when an electrical current is applied. Each of the LED devices in the array 26 may also emit light in the same peak wavelength, which for red blood cells is preferably selected to be around approximately 470 nm, and for platelets is preferably selected to be around approximately 308 nm.
  • The discrete radiation sources or lights may be arranged in banks or arrays containing multiple rows of individual lights, or may be arranged in a single row (not shown). As shown in FIG. 5, if LED devices are used, a plurality of discrete LED devices may be arranged in multiple rows. The lights may also be staggered or offset from each other (not shown). If a bank or an array of LED lights is located in both the top and the bottom of the irradiation chamber 55 (see FIG. 1), or in a vertical orientation as described above, each bag or container 10 containing fluid to be irradiated will be exposed to light on both the top and the bottom surfaces (or on both sides of the bag if in a vertical orientation). A reflective surface 17 (like that shown in FIG. 1) may also be part of the array.
  • One or more light sources may be used in the irradiation apparatus, depending on the output required to substantially inactivate viruses which may be present in the blood product, and without substantially damaging the blood component being irradiated.
  • As described above, the lights used in this invention may be LED devices or other narrow bandwidth sources such as excimer light sources. LEDs are advantageous because they emit light in a very narrow spectrum. Emitting light in a narrow spectrum may be beneficial to the blood product being irradiated because all non-useful wavelengths of light which might damage the blood or blood component being irradiated are eliminated. LED devices are available from any one of a number of companies. Some companies that manufacture LED devices useful in this invention are Cree, Inc. (Durham, N.C., USA); Nichia, Co. (Tokushima, JP); Kingbright, Corp. (City of Industry, Calif., USA) and Lumileds Lighting, LLC (San Jose, Calif., USA). In this invention, LEDs which emit light in the blue color spectrum and emit light at a peak wavelength of approximately 470 nm are most preferred for inactivating pathogens that may be contained in red blood cells. Excimer light sources or LEDs which emit light at a peak wavelength of approximately 308 nm are most preferred for irradiating pathogens that may be contained in platelets and/or plasma.
  • One type of excimer light source which may be used in the present invention are lights which emit at a peak wavelength of 308 nm (available from Ushio Corp.). As can be seen from the light spectrum shown in FIG. 6, the Ushio bulbs have a peak wavelength at approximately 308 nm, as compared to 320 nm broadband fluorescent bulbs, which generate light over a much wider spectrum. It should be noted that although Ushio bulbs are described, any light bulbs which emit light at a peak wavelength of 308 nm may be used.
  • One Ushio bulb produces a flux of around 0.04 J/cm2/min while two bulbs provide a flux of around 0.11 J/cm2/min. This is compared to the full output of 320 nm fluorescent bulbs which produce a flux of around 0.45 J/cm2/min. To irradiate platelets at an energy level of 7 J/cm2, one Ushio bulb requires 175 minutes of irradiation, while two bulbs require 64 minutes of irradiation. Three Ushio bulbs require irradiation for 24.1 minutes, while four Ushio bulbs require 14 minutes of irradiation. Two banks of four bulbs of broad spectrum 320 nm fluorescent bulbs require 15.5 minutes.
  • To determine the most effective wavelengths of light to substantially reduce pathogens in platelets and plasma without causing substantial damage to the blood components, long pass (LP) filters were initially employed. The spectral data of broad spectrum 320 nm lights which were subjected to filters which filter out light below a certain wavelength are shown in FIG. 11. A 305 LP filter, when applied to light from a 320 nm broadband source will filter out wavelengths below 305 nm. A 320 LP filter will filter out wavelengths below 320 nm. A 295 LP filter will filter out wavelengths below 295 nm. As shown in FIG. 8, light at wavelengths of 320 nm or above provide poorer viral kill as compared to light at wavelengths below 320. As seen in FIG. 8, although the use of a 305 LP filter substantially curtails the range of wavelengths delivered, viral kill appears to be much greater than that achieved using higher wavelengths of light. Therefore, the wavelengths which are not filtered out are most significant for viral kill. FIG. 8 also demonstrates that light emitted in a very narrow range around 313 nm may also be used to substantially reduce pathogens in both plasma and platelets. This graph shows that in plasma (and by analogy in platelets), the amount of virus kill tracks with a given energy dose. Furthermore, light in the 313 nm range appears to follow the amount of viral kill produced by light in the lower range (308 nm).
  • FIG. 7 is a graph comparing BVDV inactivation in plasma as a function of energy. The conditions used to substantially reduce virus in plasma are analogous to the conditions used to substantially reduce virus in platelets. BVDV was spiked into a 278 mL solution containing 90% plasma carryover. Riboflavin was added at a concentration of between 30-50 μM. Virus kill achieved using a broadband source of light having a peak wavelength of 320 nm was compared to kill achieved using a narrow bandwidth source with a peak wavelength of 308 nm and kill achieved using a broad spectrum of 320 nm light. As shown, light emitting peaks at 308 nm provided substantially the same amount of viral kill as light emitted from a broad spectrum 320 nm light source, indicating that 308 nm light is very efficient at kill.
  • Based on the results from the above studies, the quality of platelets irradiated with peak wavelengths as compared to broad spectrum light was studied over five days of storage. 30-50 μM riboflavin was added to platelets and irradiated at 7 J/cm2 for 14, 15, 24 or 122 minutes, depending on the flux produced by each type of bulb and the number of bulbs used. Platelet quality was measured using common measures of platelet quality such as % Extended Shape Change (ESC), P-selectin, lactate production, and pH. Use of peak wavelengths of light to reduce pathogens in platelets does not appear to damage platelets to the same extent as light having a broad spectrum. This is illustrated in FIGS. 9 a-d which show that the cell quality achieved with light having a wavelength of 308 nm resulted in better platelet cell quality, possibly indicating that the additional wavelengths of light that hit the cells from the broad spectrum sources may be damaging.
  • FIG. 9 a is a graph of the percentage of extended shape change of platelets over five days of storage. Extended shape change is a measure of platelets ability to respond to agonists. Irradiation of platelets with 308 nm Ushio bulbs appears to maintain a higher percentage of ESC as compared to platelets irradiated with broad spectrum 320 nm bulbs.
  • FIG. 9 b is a graph showing P-selectin expression as a function of time. P-selectin is a marker which appears on the surface of platelets when platelets are in an activated state. Platelets which are activated are more likely to aggregate together than non-activated platelets. The occurrence of aggregation has been correlated with removal of platelets from the circulation system and hence have short survival times in the body of a recipient when treated platelets are infused. It appears from FIG. 9 b that irradiation using broad spectrum light causes platelets to become more activated than platelets irradiated with light at a peak wavelength of 308 nm.
  • FIG. 9 c shows the production of lactate by platelets during storage. It has been observed that irradiated platelets have suppressed mitochondrial function. If the mitochondria of platelets is suppressed by UV light, platelets are unable to create ATP (cellular energy) through aerobic respiration. If platelets are unable to create energy through aerobic respiration, they will create energy through an alternative pathway called the glycolysis pathway. One metabolite produced by the glycolysis pathway is lactate or lactic acid. Lactic acid buildup within cells causes the pH of the solution to drop. Such a drop in pH causes decreased cell quality during storage. As shown in FIG. 9 c, platelets irradiated with broad spectrum light produced lactate at a much higher rate than platelets irradiated with light at a peak wavelength of 308 nm.
  • FIG. 9 d is a graph measuring the drop in pH of irradiated platelets over the course of five days. Drops in the pH of platelets during storage is indicative of a decrease in the quality of stored platelets. Platelets which were irradiated with broad spectrum light suffered a greater drop in pH over five days of storage than did platelets irradiated with light at 308 nm.
  • Although Ushio bulbs are given as one example of bulbs which could be used in the present invention, it should be noted that any type of bulbs, either fluorescent or LEDs which emit light at a peak wavelength between 305-313 nm may be used. Filters which filter out undesired wavelengths of light may also be used to obtain the desired peak wavelength.
  • If desired, the light sources 20 and 30 may be pulsed. Pulsing the light may be advantageous because the intensity of light produced by the light sources may be increased dramatically if the lights are allowed to be turned off and rested between light pulses. Pulsing the light at a high intensity also allows for greater depth of light penetration into the fluid being irradiated, thus allowing a thicker layer of fluid to be irradiated with each light pulse.
  • FIG. 10 shows an alternative embodiment of an irradiation or treatment chamber to be used with the present invention. A bank of light sources 50 which emit peak wavelengths of light and which may or may not be capable of being pulsed, may be located within the top of the irradiation chamber extending from lid 40. Although not shown in FIG. 10, a bank of lights may also be located in the bottom of the irradiation chamber as well. A reflective surface 57 is shown as part of the inner surface of lid 40, however, reflective surface 57 or another one or more surfaces (not shown) may be located anywhere within the radiation chamber as introduced above.
  • The lid 40 is capable of being opened and closed. During exposure of the bag 10 containing the fluid to be irradiated to the light sources, the lid 40 is in a closed position (not shown). To add or remove the bag 10 containing the fluid to be irradiated from the irradiation chamber, a drawer 45 located on the front of the irradiation chamber may be disposed in an open position (as shown). During the irradiation procedure, the drawer 45 is placed in a closed position (not shown).
  • The light sources 50 as shown in FIG. 10, may be fluorescent or incandescent tubes, which stretch the length of the irradiation chamber, or may be a single light source which extends the length and width of the entire chamber (not shown). The LEDs shown in FIG. 5 may also be used in this embodiment.
  • As shown in FIG. 10, the support platform 67 may be located within and/or forming part of drawer 45. The support platform 67 may contain gaps 60 or holes or spaces within the platform 67 to allow radiation to penetrate through the gaps directly into the container 10 containing fluid to be irradiated.
  • A cooling system may also optionally be included. As shown in FIG. 10, air cooling using at least one fan 65 may be preferred but it is understood that other well-known systems can also be used. Although not shown in FIG. 10, the method may also include the use of temperature sensors and other cooling mechanisms where necessary to keep the temperature below temperatures at which desired proteins and blood components in the fluid being irradiated are damaged. Preferably, the temperature is kept between about 0° C. and about 45° C., more preferably between about 4° C. and about 37° C, and most preferably about 28° C.
  • Although described primarily with reference to a stand alone irradiation device used to irradiate individual bags (batch process), peak wavelengths of light may be used to irradiate blood or blood components in a flow-through irradiation system as well, without departing from the scope of the present invention.

Claims (22)

1. A method for inactivating pathogens in a fluid containing plasma comprising;
adding a photosensitizer to the fluid to form a mixture, and
exposing the mixture of the fluid and the photosensitizer to light within an approximate range of between 305-313 nm.
2. A method of claim 1 wherein the step of exposing further comprises exposing the mixture to light having a peak wavelength at 308 nm.
3. The method of claim 1 wherein the exposing step further comprises exposing the mixture to pulsed light within the approximate range.
4. The method of claim 1 wherein the photosensitizer is an endogenous photosensitizer.
5. The method of claim 1 wherein the photosensitizer is an isoalloxazine.
6. The method of claim 1 wherein the photosensitizer is riboflavin.
7. The method of claim 1 further comprising:
filtering out all light except light in the range of between 305-313 nm.
8. The method of claim 7 wherein the step of filtering comprises filtering out all light in the UV spectrum except light having a peak wavelength of approximately 308 nm.
9. The method of claim 7 wherein the step of filtering comprises filtering out all light in the UV spectrum except light having a peak wavelength of approximately 313 nm.
10. A treatment chamber for inactivating pathogens in a fluid containing plasma and a photosensitizer comprising:
at least one radiation emitting source emitting radiation at a peak wavelength of approximately 308 nm;
a support platform for holding the fluid containing plasma and photosensitizer to be irradiated; and
a control unit for controlling the radiation emitting source.
11. The treatment chamber of claim 10 wherein the radiation emitting source is capable of being pulsed.
12. The treatment chamber of claim 10 wherein the control unit further controls the movement of the support platform.
13. The treatment chamber of claim 12 wherein the support platform is capable of movement in multiple directions within the treatment chamber.
14. The treatment chamber of claim 10 wherein the support platform is made of photopermeable material.
15. The treatment chamber of claim 10 wherein the chamber further comprises at least one reflective surface.
16. The treatment chamber of claim 10 wherein the support platform includes a reflective surface.
17. The treatment chamber of claim 11 and claim 12 wherein the control unit further moves the support platform in coordination with the radiation pulses.
18. The treatment chamber of claim 10 wherein the radiation emitting source further comprises an array containing a plurality of discrete lights.
19. The treatment chamber of claim 18 wherein the array containing a plurality of discrete lights further comprises a plurality of LEDs.
20. A method of irradiating plasma in a fluid contained within a photopermeable bag comprising the steps of:
adding riboflavin to the bag in an amount necessary to inactivate any pathogens contained in the fluid;
exposing the bag containing at least the fluid and riboflavin to a peak wavelength of light; and
mixing the contents of the bag during the exposing step.
21. A method of irradiating a fluid containing plasma comprising the steps of:
adding an amount of photosensitizer to the fluid necessary to inactivate any pathogens contained in the fluid;
exposing the fluid and photosensitizer to light at a wavelength of approximately 308 nm; and
mixing the fluid and photosensitizer during the exposing step to expose the majority of the fluid to the light.
22. A method of irradiating a blood product comprising the steps of:
a) adding an amount of photosensitizer necessary to inactivate any pathogens contained in the blood product;
b) pulsing a radiation source having a peak wavelength of light of approximately 308 nm to expose the blood product and photosensitizer to radiation at the peak wavelength;
c) pulsing the radiation source off to stop exposure of the blood product and photosensitizer to radiation;
d) mixing the blood product and photosensitizer during the step of pulsing the radiation source off; and
e) repeating steps b), c) and d).
US10/904,361 2000-06-15 2004-11-05 Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light Abandoned US20050112021A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/904,361 US20050112021A1 (en) 2000-06-15 2004-11-05 Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light
US11/840,759 US9044523B2 (en) 2000-06-15 2007-08-17 Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/596,429 US7094378B1 (en) 2000-06-15 2000-06-15 Method and apparatus for inactivation of biological contaminants using photosensitizers
US23599900P 2000-09-27 2000-09-27
US09/962,029 US20020015662A1 (en) 2000-06-15 2001-09-25 Inactivation of contaminants using photosensitizers and pulsed light
US35322302P 2002-02-01 2002-02-01
US10/357,599 US6843961B2 (en) 2000-06-15 2003-02-03 Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US10/904,361 US20050112021A1 (en) 2000-06-15 2004-11-05 Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10357599 Continuation 2002-02-03
US10/357,599 Continuation US6843961B2 (en) 2000-06-15 2003-02-03 Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/840,759 Continuation-In-Part US9044523B2 (en) 2000-06-15 2007-08-17 Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light

Publications (1)

Publication Number Publication Date
US20050112021A1 true US20050112021A1 (en) 2005-05-26

Family

ID=34596185

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/357,599 Expired - Lifetime US6843961B2 (en) 2000-06-15 2003-02-03 Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US10/904,361 Abandoned US20050112021A1 (en) 2000-06-15 2004-11-05 Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/357,599 Expired - Lifetime US6843961B2 (en) 2000-06-15 2003-02-03 Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light

Country Status (1)

Country Link
US (2) US6843961B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178437A1 (en) * 2006-01-27 2007-08-02 Hansen Eric T Methods and compositions for the production of high concentration alloxazine solutions
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
US20140217307A1 (en) * 2013-02-05 2014-08-07 EGOHEALTH S.r.l. Device for the hygienisation of medical instruments

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049110B2 (en) * 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US6843961B2 (en) * 2000-06-15 2005-01-18 Gambro, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US7398935B2 (en) * 2004-05-14 2008-07-15 Nalco Company Methods and compositions for dust control and freeze control
JP4899040B2 (en) * 2005-07-01 2012-03-21 国立大学法人 岡山大学 Bilirubin denaturator and bilirubin dialysis machine
US20070102858A1 (en) * 2005-11-07 2007-05-10 Navigant Biotechnologies, Inc. Clamps and methods for displacing fluid from portions of fluid containers
US8834788B2 (en) * 2006-05-04 2014-09-16 Fogg Filler Company Method for sanitizing/sterilizing a container/enclosure via controlled exposure to electromagnetic radiation
US20100330523A1 (en) * 2007-03-30 2010-12-30 Cms Dental Aps Optical tip for photosynthesis
WO2009005853A1 (en) 2007-07-02 2009-01-08 Caridianbct Biotechnologies, Llc Apparatus for photo reduction of contaminants in blood and blood products with calibration means
CN101868255A (en) * 2007-08-01 2010-10-20 科安比司特生物技术有限责任公司 Whole blood pathogen inactivated
WO2009026073A1 (en) * 2007-08-22 2009-02-26 Caridianbct Biotechnologies, Llc Prevention of transfusion related acute lung injury using riboflavin and light
US20100282980A1 (en) * 2009-05-11 2010-11-11 Caridianbct Biotechnologies, Llc Stable Calibration Means for Apparatus for Photo Reduction of Contaminants in Blood
US8753807B2 (en) * 2009-06-02 2014-06-17 Biolitec Pharma Marketing Ltd Method for microbes depletion in human blood or full serum using antimicrobial photodynamic laser therapy
CA2777014A1 (en) * 2009-10-16 2011-04-21 Hospira, Inc. Ultraviolet sterilization system
JP5945228B2 (en) * 2010-01-19 2016-07-05 バイオリテック ファーマ マーケティング リミテッド Enhanced antibacterial PDT
US9011733B2 (en) 2011-12-21 2015-04-21 Joan Lynch Dielectric fluids compositions and methods
WO2013106605A1 (en) 2012-01-11 2013-07-18 Terumo Bct Biotechnologies, Llc Slidable clamp for port isolation
GB201500512D0 (en) * 2015-01-13 2015-02-25 Soe Health Ltd Therapeutic treatment methods, and apparatus for use therein
US20170028121A1 (en) * 2015-07-31 2017-02-02 Fenwal, Inc. Irradiation device for biological fluids
US10675369B1 (en) * 2017-04-10 2020-06-09 Altapure, Llc Rotating object holder for multi-function sanitization, disinfection, and sterilization in a cabinet
CN111770789B (en) 2017-12-29 2023-05-05 塞鲁斯公司 System and method for processing biological fluids
EP3616750A1 (en) * 2018-08-27 2020-03-04 S1 Sähkö Oy System and method for reducing microorganisms
AU2020303972A1 (en) 2019-06-22 2022-02-10 Cerus Corporation Systems and methods for implementing treatment of biological fluids
CA3143213A1 (en) 2019-06-22 2020-12-30 Cerus Corporation Biological fluid treatment systems
CN114269394A (en) 2019-06-28 2022-04-01 塞鲁斯公司 System and method for implementing a biological fluid treatment device
WO2021262883A1 (en) * 2020-06-24 2021-12-30 Amplify Solutions, Inc. Systems and methods for uv decontamination of respirators
IL302136A (en) 2020-10-19 2023-06-01 Cerus Corp Modular light device for a biological fluid treatment system
CN114177536A (en) * 2021-12-03 2022-03-15 北京翌光医疗科技研究院有限公司 Light emitting device
CN114366831A (en) * 2022-01-10 2022-04-19 南京双威生物医学科技有限公司 Plasma pathogen inactivation treatment method based on riboflavin photochemical method

Citations (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1961700A (en) * 1932-07-29 1934-06-05 Gen Electric Vapor Lamp Co Apparatus for sterilizing articles by ultraviolet radiation
US2111491A (en) * 1935-01-26 1938-03-15 Winthrop Chem Co Inc Process of preparing phosphoric acid esters of hydroxyalkyl isoalloxazines
US2340890A (en) * 1941-02-25 1944-02-08 Lang Alphonse Method and apparatus for sterilizing, preserving, and irradiating of various liquid substances
US2825729A (en) * 1955-05-24 1958-03-04 Upjohn Co Isoalloxazines
US3189598A (en) * 1960-01-14 1965-06-15 Yagi Kunio Fatty acid esters of riboflavin
US3864081A (en) * 1973-06-12 1975-02-04 Spectroderm International Inc Apparatus for sterilizing biologic material and the like by ultra-violet irradiation
US4181128A (en) * 1975-11-28 1980-01-01 Massachusetts Institute Of Technology Virus inactivation applicator and the like
US4196281A (en) * 1976-10-20 1980-04-01 Regents Of The University Of California Psoralens
US4312883A (en) * 1979-08-20 1982-01-26 Consiglio Nazionale Delle Ricerche Furocoumarin for the photochemotherapy of psoriasis and related skin diseases
US4321918A (en) * 1979-10-23 1982-03-30 Clark Ii William T Process for suppressing immunity to transplants
US4321919A (en) * 1979-12-11 1982-03-30 Leukocyte Research, Inc. Method and system for externally treating human blood
US4336809A (en) * 1980-03-17 1982-06-29 Burleigh Instruments, Inc. Human and animal tissue photoradiation system and method
US4424201A (en) * 1978-11-28 1984-01-03 Rockefeller University Employment of a mereyanine dye for the detection of malignant leukocytic cells
US4428744A (en) * 1979-12-11 1984-01-31 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4456512A (en) * 1982-03-10 1984-06-26 The Dow Chemical Company Photochemical reactor and method
US4493981A (en) * 1984-03-05 1985-01-15 General Electric Company Boil dry protection system for cooking appliance
US4565328A (en) * 1983-08-08 1986-01-21 Combustion Engineering, Inc. Sand reclamation system with thermal pipe reclaimer apparatus
US4573961A (en) * 1984-10-29 1986-03-04 Extracorporeal Medical Specialties, Inc. Electronic control methods for puvapheresis apparatus
US4573960A (en) * 1984-10-29 1986-03-04 Extracorporeal Medical Specialties, Inc. Three phase irradiation treatment process
US4573962A (en) * 1984-10-29 1986-03-04 Extracorporeal Medical Specialties, Inc. Cassette drawer assembly for photoactivation patient treatment system
US4576143A (en) * 1984-10-05 1986-03-18 Clark Iii William T Method of immune modification by means of extracorporeal irradiation of the blood
US4578056A (en) * 1984-10-29 1986-03-25 Extracorporeal Medical Specialties, Inc. Patient photopheresis treatment apparatus and method
US4596547A (en) * 1984-10-29 1986-06-24 Mcneilab, Inc. Valve apparatus for photoactivation patient treatment system
US4642171A (en) * 1984-09-18 1987-02-10 Kabushiki Kaisha Toshiba Phototreating apparatus
US4645649A (en) * 1981-04-27 1987-02-24 G-C Dental Industrial Corp. Apparatus for curing resin films coated on dental resin prosthesis
US4648992A (en) * 1984-02-17 1987-03-10 Ciba-Geigy Corporation Water-soluble phthalocyanine compounds
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4651739A (en) * 1985-04-08 1987-03-24 The General Hospital Corporation Light-induced killing of carcinoma cells
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4726949A (en) * 1986-08-26 1988-02-23 Baxter Travenol Laboratories, Inc. Irradiation of blood products
US4737140A (en) * 1984-10-29 1988-04-12 Mcneilab, Inc. Irradiation chamber for photoactivation patient treatment system
US4748120A (en) * 1983-05-02 1988-05-31 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4831268A (en) * 1985-03-20 1989-05-16 VEB Elektro-und Metallgerate Ilmenau Method for the physiologically & therapeutically effective irradiation of corporeal venous blood
US4833165A (en) * 1987-10-07 1989-05-23 Louderback Allan Lee Method of inactivating HTLV-III virus in blood
US4910942A (en) * 1983-11-23 1990-03-27 Maxwell Laboratories, Inc. Methods for aseptic packaging of medical devices
US4915683A (en) * 1986-11-21 1990-04-10 The Medical College Of Wisconsin, Inc. Antiviral method, agents and apparatus
US4921473A (en) * 1989-02-02 1990-05-01 Therakos, Inc. Multicomponent fluid separation and irradiation system
US4930516A (en) * 1985-11-13 1990-06-05 Alfano Robert R Method for detecting cancerous tissue using visible native luminescence
US4986628A (en) * 1988-08-23 1991-01-22 Lozhenko Alexandr S Light guide device for phototherapy
US4992363A (en) * 1983-11-09 1991-02-12 Thomas Jefferson University Method for preparing glucose free media for storing blood platelets
US5011695A (en) * 1988-02-22 1991-04-30 Biotest Pharma Gmbh Sterilization of blood and its derivatives with vitamins
US5017338A (en) * 1986-04-11 1991-05-21 The Center For Blood Research, Inc. Platelet concentrates
US5089146A (en) * 1990-02-12 1992-02-18 Miles Inc. Pre-storage filtration of platelets
US5089384A (en) * 1988-11-04 1992-02-18 Amoco Corporation Method and apparatus for selective cell destruction using amplified immunofluorescence
US5092773A (en) * 1989-01-18 1992-03-03 Endo Technic Corporation Method and apparatus for filling a tooth canal
US5095115A (en) * 1989-09-14 1992-03-10 Basf Aktiengesellschaft Preparation of riboflavin 5'-phosphate (fmn) and its sodium salt in a lactone
US5114670A (en) * 1990-08-30 1992-05-19 Liqui-Box/B-Bar-B Corporation Process for sterilizing surfaces
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5184020A (en) * 1989-10-26 1993-02-02 Hearst David P Device and method for photoactivation
US5185532A (en) * 1991-05-21 1993-02-09 Oral Card Products Dental instrument sterilizer
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5288605A (en) * 1992-03-02 1994-02-22 Steritech, Inc. Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen
US5288647A (en) * 1988-05-02 1994-02-22 Stratagene Method of irradiating biological specimens
US5290221A (en) * 1990-12-20 1994-03-01 Baxter International Inc. Systems for eradicating contaminants using photoactive materials in fluids like blood
US5300019A (en) * 1990-12-20 1994-04-05 Baxter International Inc. Systems and methods for eradicating contaminants using photoactive materials in fluids like blood
US5304113A (en) * 1986-11-21 1994-04-19 The Mcw Research Foundation, Inc. Method of eradicating infectious biological contaminants
US5378601A (en) * 1992-07-24 1995-01-03 Montefiore Medical Center Method of preserving platelets with apyrase and an antioxidant
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5419759A (en) * 1988-11-17 1995-05-30 Naficy; Sadeque S. Apparatus and methods for treatment of HIV infections and AIDS
US5482828A (en) * 1992-03-02 1996-01-09 Steritech, Inc. Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5484778A (en) * 1990-07-17 1996-01-16 University Hospitals Of Cleveland Phthalocyanine photosensitizers for photodynamic therapy and methods for their use
US5487971A (en) * 1986-03-19 1996-01-30 American National Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US5489442A (en) * 1994-04-18 1996-02-06 Purepulse Technologies, Inc. Prolongation of shelf-life in perishable food products
US5503721A (en) * 1991-07-18 1996-04-02 Hri Research, Inc. Method for photoactivation
US5516629A (en) * 1990-04-16 1996-05-14 Cryopharm Corporation Photoinactivation of viral and bacterial blood contaminants using halogenated coumarins
US5593823A (en) * 1993-06-28 1997-01-14 Cerus Corporation Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens
US5597722A (en) * 1993-01-28 1997-01-28 Baxter International Inc. Method for inactivating pathogens in compositions containing cells and plasma using photoactive compounds and plasma protein reduction
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5622867A (en) * 1994-10-19 1997-04-22 Lifecell Corporation Prolonged preservation of blood platelets
US5624435A (en) * 1995-06-05 1997-04-29 Cynosure, Inc. Ultra-long flashlamp-excited pulse dye laser for therapy and method therefor
US5628727A (en) * 1995-08-15 1997-05-13 Hakky; Said I. Extracorporeal virioncidal apparatus
US5707401A (en) * 1994-03-10 1998-01-13 Esc Medical Systems, Ltd. Apparatus for an efficient photodynamic treatment
US5709991A (en) * 1992-03-02 1998-01-20 Cerus Corporation Proralen inactivation of microorganisms and psoralen removal
US5709653A (en) * 1996-07-25 1998-01-20 Cordis Corporation Photodynamic therapy balloon catheter with microporous membrane
US5712086A (en) * 1990-05-15 1998-01-27 New York Blood Center, Inc. Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins
US5739013A (en) * 1993-09-24 1998-04-14 Budowsky; Edward I. Enzymatic synthesis of 2',5'-oligoadenylate-2',3'-cyclophosphates and treatment of papillomaviruses
US5743459A (en) * 1994-10-14 1998-04-28 Nec Corporation Method for fabricating semiconductor device with step of bonding lead frame leads to chip pads
US5756553A (en) * 1993-07-21 1998-05-26 Otsuka Pharmaceutical Factory, Inc. Medical material and process for producing the same
US5866074A (en) * 1996-12-20 1999-02-02 Baxter International Inc. Systems for quantifying the illumination characteristics of vessels such as blood processing containers with respect to light energy
US5868695A (en) * 1990-12-20 1999-02-09 Baxter International Inc. Systems and methods for eradicating contaminants using photoactive materials in fluids like blood using discrete sources of radiation
US5871900A (en) * 1993-06-28 1999-02-16 Cerus Corporation Method of inactivating pathogens in biological fluids using photoactivated 5-primaryamino psoralens
US5876676A (en) * 1993-02-18 1999-03-02 Brigham And Women's Hospital, Inc. Preservation of blood platelets
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US5900211A (en) * 1995-10-26 1999-05-04 Purepulse Technologies Deactivation of organisms using high-intensity pulsed polychromatic light
US6013918A (en) * 1996-02-15 2000-01-11 Purepulse Technologies, Inc. Deactivation of microorganisms
US6020333A (en) * 1994-04-11 2000-02-01 Berque; Jean Compositions containing in particular, riboflavin, for the local prevention of diseases of the genital and rectal mucus membranes
US6054097A (en) * 1998-08-03 2000-04-25 Innovatech Expanding plasma emission source microorganism inactivation system
US6200287B1 (en) * 1997-09-05 2001-03-13 Gambro, Inc. Extracorporeal blood processing methods and apparatus
US6348309B1 (en) * 1989-09-13 2002-02-19 Blutspendedienst Der Landesverbaende Des Deutschen Roten Kreuzes Niedersachsen, Oldenburg Und Bremen G.G.M.B.H. Process for inactivating viruses in blood and blood products
US20030085173A1 (en) * 1999-06-03 2003-05-08 Degheldere Serge Processing set and methods for processing and treating a biological fluid
US6565802B1 (en) * 1999-06-03 2003-05-20 Baxter International Inc. Apparatus, systems and methods for processing and treating a biological fluid with light
US20040072139A1 (en) * 2000-07-04 2004-04-15 Harald Mohr Photodynamic treatment and uv-b-irradiation of a thrombocyte suspension
US20040088189A1 (en) * 2002-11-06 2004-05-06 Veome Edmond A. System and method for monitoring , reporting, managing and administering the treatment of a blood component
US6843961B2 (en) * 2000-06-15 2005-01-18 Gambro, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6855489B1 (en) * 1996-10-28 2005-02-15 Baxter International Inc. Systems and methods for removing viral agents from blood

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167669A (en) 1971-09-09 1979-09-11 Xenon Corporation Apparatus for rapid curing of resinous materials and method
JPS56161054A (en) 1980-05-15 1981-12-11 Ushio Electric Inc Sterilizing method
EP0087441A1 (en) 1981-09-08 1983-09-07 Quentron Optics Pty. Ltd. Photoradiation method and arrangement
US5034235A (en) 1983-11-23 1991-07-23 Maxwell Laboratories, Inc. Methods for presevation of foodstuffs
US4871559A (en) 1983-11-23 1989-10-03 Maxwell Laboratories, Inc. Methods for preservation of foodstuffs
US4880512A (en) 1984-02-16 1989-11-14 Kollmorgen Corporation Pulsed light selective photolysis process for treatment of biological media and products made thereby
US4866282A (en) 1986-08-26 1989-09-12 Baxter International Inc. Irradiation of blood products
US4952812A (en) 1986-08-26 1990-08-28 Baxter International Inc. Irradiation of blood products
DE3881473T2 (en) 1987-10-22 1993-09-09 Duthie Jun Robert E METHOD AND STERILIZATION DEVICE.
IL84367A (en) 1987-11-04 1994-02-27 Amcor Ltd Apparatus for use in radiation therapy
US5658722A (en) 1990-05-15 1997-08-19 New York Blood Center, Inc. Process for the sterilization of biological compositions using UVA1 irradiation
US5645796A (en) 1990-08-31 1997-07-08 Abtox, Inc. Process for plasma sterilizing with pulsed antimicrobial agent treatment
US5235045A (en) 1992-03-19 1993-08-10 Microbiomed Corporation Non-azo naphthalimide dyes
CA2092373A1 (en) 1992-04-24 1993-10-25 Klaus W. Berndt Methods and apparatus for detecting biological activities in a specimen
EP0637976B2 (en) 1992-04-30 2002-10-16 Eastman Dental Institute Medicament for disinfection of the oral cavity
DE4235841A1 (en) 1992-10-23 1994-04-28 Steiger Erwin Laser systems providing selective destruction esp. for HIV virus - has two tunable lasers for extracorporeal and intra-corporeal irradiation
US6004741A (en) 1993-06-28 1999-12-21 Cerus Corporation Method for the photoactivation of 4' and 5' primary aminoalkyl psoralens in platelet preparations
WO1995002325A1 (en) 1993-07-12 1995-01-26 Baxter International Inc. Apparatus and method for inactivating viral contaminants in body fluids
US5762867A (en) 1994-09-01 1998-06-09 Baxter International Inc. Apparatus and method for activating photoactive agents
US5698866A (en) 1994-09-19 1997-12-16 Pdt Systems, Inc. Uniform illuminator for phototherapy
WO1996009776A1 (en) 1994-09-27 1996-04-04 Purepulse Technologies, Inc. Photocatalyst and pulsed light synergism in deactivation of contaminants
US5527704A (en) 1994-12-06 1996-06-18 Baxter International Inc. Apparatus and method for inactivating viral contaminants in body fluids
US6158319A (en) 1994-12-20 2000-12-12 Baxter International Inc. System to identify the status of bags that have been subjected to viral inactivation
US5786598A (en) 1996-05-22 1998-07-28 Purepulse Technologies, Inc. Sterilization of packages and their contents using high-intensity, short-duration pulses of incoherent, polychromatic light in a broad spectrum
US5925885A (en) 1996-05-22 1999-07-20 Purepulse Technologies, Inc. Parametric control in pulsed light sterilization of packages and their contents
AT406778B (en) 1996-04-09 2000-09-25 Immuno Ag METHOD FOR DISINEGRATING NUCLEIC ACIDS AND PRODUCING QUALITY-ASSURED BIOLOGICAL PRODUCTS
US5798523A (en) 1996-07-19 1998-08-25 Theratechnologies Inc. Irradiating apparatus using a scanning light source for photodynamic treatment
US5922278A (en) 1996-11-19 1999-07-13 Baxter International Inc. Method and apparatus for inactivating contaminants in biological fluid
US6190609B1 (en) 1996-11-19 2001-02-20 Baxter International Inc. Methods and apparatus for inactivating contaminants in biological fluid
US5951509A (en) 1996-11-22 1999-09-14 Therakos, Inc. Blood product irradiation device incorporating agitation
US6258577B1 (en) * 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
DE60017243T2 (en) 1999-02-13 2005-12-08 Purepulse Technologies, Inc., San Diego METHOD FOR INACTIVATING PATHOGENIC BY WIDE SPECTRUM PULSE LIGHT
WO2001023007A1 (en) 1999-09-24 2001-04-05 Iotron Industries Canada Inc. Electron beam sterilization of contained liquids
US6268120B1 (en) * 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US6312931B1 (en) * 2000-02-11 2001-11-06 Purepulse Technologies, Inc. Protecting molecules in biologically derived compositions while treating with high intensity broad-spectrum pulsed light

Patent Citations (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1961700A (en) * 1932-07-29 1934-06-05 Gen Electric Vapor Lamp Co Apparatus for sterilizing articles by ultraviolet radiation
US2111491A (en) * 1935-01-26 1938-03-15 Winthrop Chem Co Inc Process of preparing phosphoric acid esters of hydroxyalkyl isoalloxazines
US2340890A (en) * 1941-02-25 1944-02-08 Lang Alphonse Method and apparatus for sterilizing, preserving, and irradiating of various liquid substances
US2825729A (en) * 1955-05-24 1958-03-04 Upjohn Co Isoalloxazines
US3189598A (en) * 1960-01-14 1965-06-15 Yagi Kunio Fatty acid esters of riboflavin
US3864081A (en) * 1973-06-12 1975-02-04 Spectroderm International Inc Apparatus for sterilizing biologic material and the like by ultra-violet irradiation
US4181128A (en) * 1975-11-28 1980-01-01 Massachusetts Institute Of Technology Virus inactivation applicator and the like
US4196281A (en) * 1976-10-20 1980-04-01 Regents Of The University Of California Psoralens
US4424201A (en) * 1978-11-28 1984-01-03 Rockefeller University Employment of a mereyanine dye for the detection of malignant leukocytic cells
US4312883A (en) * 1979-08-20 1982-01-26 Consiglio Nazionale Delle Ricerche Furocoumarin for the photochemotherapy of psoriasis and related skin diseases
US4321918A (en) * 1979-10-23 1982-03-30 Clark Ii William T Process for suppressing immunity to transplants
US4321918B1 (en) * 1979-10-23 1984-09-04
US4321919A (en) * 1979-12-11 1982-03-30 Leukocyte Research, Inc. Method and system for externally treating human blood
US4428744A (en) * 1979-12-11 1984-01-31 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4336809A (en) * 1980-03-17 1982-06-29 Burleigh Instruments, Inc. Human and animal tissue photoradiation system and method
US4645649A (en) * 1981-04-27 1987-02-24 G-C Dental Industrial Corp. Apparatus for curing resin films coated on dental resin prosthesis
US4456512A (en) * 1982-03-10 1984-06-26 The Dow Chemical Company Photochemical reactor and method
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4748120A (en) * 1983-05-02 1988-05-31 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4565328A (en) * 1983-08-08 1986-01-21 Combustion Engineering, Inc. Sand reclamation system with thermal pipe reclaimer apparatus
US4992363A (en) * 1983-11-09 1991-02-12 Thomas Jefferson University Method for preparing glucose free media for storing blood platelets
US4910942A (en) * 1983-11-23 1990-03-27 Maxwell Laboratories, Inc. Methods for aseptic packaging of medical devices
US4648992A (en) * 1984-02-17 1987-03-10 Ciba-Geigy Corporation Water-soluble phthalocyanine compounds
US4493981A (en) * 1984-03-05 1985-01-15 General Electric Company Boil dry protection system for cooking appliance
US4642171A (en) * 1984-09-18 1987-02-10 Kabushiki Kaisha Toshiba Phototreating apparatus
US4576143A (en) * 1984-10-05 1986-03-18 Clark Iii William T Method of immune modification by means of extracorporeal irradiation of the blood
US4596547A (en) * 1984-10-29 1986-06-24 Mcneilab, Inc. Valve apparatus for photoactivation patient treatment system
US4578056A (en) * 1984-10-29 1986-03-25 Extracorporeal Medical Specialties, Inc. Patient photopheresis treatment apparatus and method
US4573962A (en) * 1984-10-29 1986-03-04 Extracorporeal Medical Specialties, Inc. Cassette drawer assembly for photoactivation patient treatment system
US4573961A (en) * 1984-10-29 1986-03-04 Extracorporeal Medical Specialties, Inc. Electronic control methods for puvapheresis apparatus
US4737140A (en) * 1984-10-29 1988-04-12 Mcneilab, Inc. Irradiation chamber for photoactivation patient treatment system
US4573960A (en) * 1984-10-29 1986-03-04 Extracorporeal Medical Specialties, Inc. Three phase irradiation treatment process
US4831268A (en) * 1985-03-20 1989-05-16 VEB Elektro-und Metallgerate Ilmenau Method for the physiologically & therapeutically effective irradiation of corporeal venous blood
US4651739A (en) * 1985-04-08 1987-03-24 The General Hospital Corporation Light-induced killing of carcinoma cells
US4930516B1 (en) * 1985-11-13 1998-08-04 Laser Diagnostic Instr Inc Method for detecting cancerous tissue using visible native luminescence
US4930516A (en) * 1985-11-13 1990-06-05 Alfano Robert R Method for detecting cancerous tissue using visible native luminescence
US5487971A (en) * 1986-03-19 1996-01-30 American National Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US5017338A (en) * 1986-04-11 1991-05-21 The Center For Blood Research, Inc. Platelet concentrates
US4726949A (en) * 1986-08-26 1988-02-23 Baxter Travenol Laboratories, Inc. Irradiation of blood products
US4915683A (en) * 1986-11-21 1990-04-10 The Medical College Of Wisconsin, Inc. Antiviral method, agents and apparatus
US5304113A (en) * 1986-11-21 1994-04-19 The Mcw Research Foundation, Inc. Method of eradicating infectious biological contaminants
US4833165A (en) * 1987-10-07 1989-05-23 Louderback Allan Lee Method of inactivating HTLV-III virus in blood
US5011695A (en) * 1988-02-22 1991-04-30 Biotest Pharma Gmbh Sterilization of blood and its derivatives with vitamins
US5288647A (en) * 1988-05-02 1994-02-22 Stratagene Method of irradiating biological specimens
US4986628A (en) * 1988-08-23 1991-01-22 Lozhenko Alexandr S Light guide device for phototherapy
US5089384A (en) * 1988-11-04 1992-02-18 Amoco Corporation Method and apparatus for selective cell destruction using amplified immunofluorescence
US5419759A (en) * 1988-11-17 1995-05-30 Naficy; Sadeque S. Apparatus and methods for treatment of HIV infections and AIDS
US5092773A (en) * 1989-01-18 1992-03-03 Endo Technic Corporation Method and apparatus for filling a tooth canal
US4921473A (en) * 1989-02-02 1990-05-01 Therakos, Inc. Multicomponent fluid separation and irradiation system
US6348309B1 (en) * 1989-09-13 2002-02-19 Blutspendedienst Der Landesverbaende Des Deutschen Roten Kreuzes Niedersachsen, Oldenburg Und Bremen G.G.M.B.H. Process for inactivating viruses in blood and blood products
US5095115A (en) * 1989-09-14 1992-03-10 Basf Aktiengesellschaft Preparation of riboflavin 5'-phosphate (fmn) and its sodium salt in a lactone
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5184020A (en) * 1989-10-26 1993-02-02 Hearst David P Device and method for photoactivation
US5089146A (en) * 1990-02-12 1992-02-18 Miles Inc. Pre-storage filtration of platelets
US5869701A (en) * 1990-04-16 1999-02-09 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US5516629A (en) * 1990-04-16 1996-05-14 Cryopharm Corporation Photoinactivation of viral and bacterial blood contaminants using halogenated coumarins
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5712086A (en) * 1990-05-15 1998-01-27 New York Blood Center, Inc. Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions
US5484778A (en) * 1990-07-17 1996-01-16 University Hospitals Of Cleveland Phthalocyanine photosensitizers for photodynamic therapy and methods for their use
US5484778C1 (en) * 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
US5114670A (en) * 1990-08-30 1992-05-19 Liqui-Box/B-Bar-B Corporation Process for sterilizing surfaces
US5868695A (en) * 1990-12-20 1999-02-09 Baxter International Inc. Systems and methods for eradicating contaminants using photoactive materials in fluids like blood using discrete sources of radiation
US5300019A (en) * 1990-12-20 1994-04-05 Baxter International Inc. Systems and methods for eradicating contaminants using photoactive materials in fluids like blood
US5290221A (en) * 1990-12-20 1994-03-01 Baxter International Inc. Systems for eradicating contaminants using photoactive materials in fluids like blood
US5185532A (en) * 1991-05-21 1993-02-09 Oral Card Products Dental instrument sterilizer
US5503721A (en) * 1991-07-18 1996-04-02 Hri Research, Inc. Method for photoactivation
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5288605A (en) * 1992-03-02 1994-02-22 Steritech, Inc. Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen
US5482828A (en) * 1992-03-02 1996-01-09 Steritech, Inc. Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5709991A (en) * 1992-03-02 1998-01-20 Cerus Corporation Proralen inactivation of microorganisms and psoralen removal
US5378601A (en) * 1992-07-24 1995-01-03 Montefiore Medical Center Method of preserving platelets with apyrase and an antioxidant
US5597722A (en) * 1993-01-28 1997-01-28 Baxter International Inc. Method for inactivating pathogens in compositions containing cells and plasma using photoactive compounds and plasma protein reduction
US5876676A (en) * 1993-02-18 1999-03-02 Brigham And Women's Hospital, Inc. Preservation of blood platelets
US5871900A (en) * 1993-06-28 1999-02-16 Cerus Corporation Method of inactivating pathogens in biological fluids using photoactivated 5-primaryamino psoralens
US5593823A (en) * 1993-06-28 1997-01-14 Cerus Corporation Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens
US5756553A (en) * 1993-07-21 1998-05-26 Otsuka Pharmaceutical Factory, Inc. Medical material and process for producing the same
US5739013A (en) * 1993-09-24 1998-04-14 Budowsky; Edward I. Enzymatic synthesis of 2',5'-oligoadenylate-2',3'-cyclophosphates and treatment of papillomaviruses
US5707401A (en) * 1994-03-10 1998-01-13 Esc Medical Systems, Ltd. Apparatus for an efficient photodynamic treatment
US6020333A (en) * 1994-04-11 2000-02-01 Berque; Jean Compositions containing in particular, riboflavin, for the local prevention of diseases of the genital and rectal mucus membranes
US5489442A (en) * 1994-04-18 1996-02-06 Purepulse Technologies, Inc. Prolongation of shelf-life in perishable food products
US5743459A (en) * 1994-10-14 1998-04-28 Nec Corporation Method for fabricating semiconductor device with step of bonding lead frame leads to chip pads
US5622867A (en) * 1994-10-19 1997-04-22 Lifecell Corporation Prolonged preservation of blood platelets
US5624435A (en) * 1995-06-05 1997-04-29 Cynosure, Inc. Ultra-long flashlamp-excited pulse dye laser for therapy and method therefor
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins
US5628727A (en) * 1995-08-15 1997-05-13 Hakky; Said I. Extracorporeal virioncidal apparatus
US5900211A (en) * 1995-10-26 1999-05-04 Purepulse Technologies Deactivation of organisms using high-intensity pulsed polychromatic light
US6228332B1 (en) * 1995-10-26 2001-05-08 Purepulse Technologies Deactivation of organisms using high-intensity pulsed polychromatic light
US6013918A (en) * 1996-02-15 2000-01-11 Purepulse Technologies, Inc. Deactivation of microorganisms
US5709653A (en) * 1996-07-25 1998-01-20 Cordis Corporation Photodynamic therapy balloon catheter with microporous membrane
US6855489B1 (en) * 1996-10-28 2005-02-15 Baxter International Inc. Systems and methods for removing viral agents from blood
US5866074A (en) * 1996-12-20 1999-02-02 Baxter International Inc. Systems for quantifying the illumination characteristics of vessels such as blood processing containers with respect to light energy
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6200287B1 (en) * 1997-09-05 2001-03-13 Gambro, Inc. Extracorporeal blood processing methods and apparatus
US6054097A (en) * 1998-08-03 2000-04-25 Innovatech Expanding plasma emission source microorganism inactivation system
US20030085173A1 (en) * 1999-06-03 2003-05-08 Degheldere Serge Processing set and methods for processing and treating a biological fluid
US6565802B1 (en) * 1999-06-03 2003-05-20 Baxter International Inc. Apparatus, systems and methods for processing and treating a biological fluid with light
US6986867B2 (en) * 1999-06-03 2006-01-17 Baxter International Inc. Apparatus, systems and methods for processing and treating a biological fluid with light
US6843961B2 (en) * 2000-06-15 2005-01-18 Gambro, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US20040072139A1 (en) * 2000-07-04 2004-04-15 Harald Mohr Photodynamic treatment and uv-b-irradiation of a thrombocyte suspension
US20040088189A1 (en) * 2002-11-06 2004-05-06 Veome Edmond A. System and method for monitoring , reporting, managing and administering the treatment of a blood component

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178437A1 (en) * 2006-01-27 2007-08-02 Hansen Eric T Methods and compositions for the production of high concentration alloxazine solutions
WO2007089538A1 (en) 2006-01-27 2007-08-09 Navigant Biotechnologies, Llc Methods and compositions for the production of high concentration alloxazine solutions
US8044051B2 (en) 2006-01-27 2011-10-25 Caridianbct Biotechnologies, Llc Methods and compositions for the production of high concentration alloxazine solutions
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
US20140217307A1 (en) * 2013-02-05 2014-08-07 EGOHEALTH S.r.l. Device for the hygienisation of medical instruments
US9114184B2 (en) * 2013-02-05 2015-08-25 EGOHEALTH S.r.l. Device for the hygienisation of medical instruments
CN104968370A (en) * 2013-02-05 2015-10-07 易购艾斯责任有限公司 Device for the hygienisation of medical instruments

Also Published As

Publication number Publication date
US6843961B2 (en) 2005-01-18
US20030219354A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
US6843961B2 (en) Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
EP1289991B1 (en) Method for inactivation of microorganisms using photosensitizers
CA2474242C (en) Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US20020015662A1 (en) Inactivation of contaminants using photosensitizers and pulsed light
AU744978B2 (en) Method and apparatus for inactivation of biological contaminants using photosensitizers
US8339592B2 (en) Apparatus for photo reduction of contaminants in blood and blood products with calibration means
CA2397862C (en) Storage solution containing photosensitizer for inactivation of biological contaminants
WO2002026270A2 (en) Inactivation of contaminants using photosensitizers and pulsed light
WO2000004930A2 (en) Method for inactivation of microorganisms using photosensitizers
EP1471940B1 (en) Inactivation of west nile virus and plasmodium falciparum using alloxazine-derivating photosensitisers
US9044523B2 (en) Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
EP1286996A1 (en) Method and apparatus for inactivation of biological contaminants using photosensitizers
US20030215784A1 (en) Method and apparatus for inactivation of biological contaminants using photosensitizers
EP1404379A2 (en) Viral inactivation process using antioxidant
US20030141260A1 (en) Oxygen-enhanced pathogen inactivation
US20030073650A1 (en) Method and apparatus for inactivation of biological contaminants using photosensitizers
US7049110B2 (en) Inactivation of West Nile virus and malaria using photosensitizers
AU770614B2 (en) Method and apparatus for inactivation of biological contaminants using photosensitizers

Legal Events

Date Code Title Description
AS Assignment

Owner name: GAMBRO BCT, INC.,COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GAMBRO, INC.;REEL/FRAME:018787/0264

Effective date: 20061218

Owner name: GAMBRO BCT, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GAMBRO, INC.;REEL/FRAME:018787/0264

Effective date: 20061218

AS Assignment

Owner name: NAVIGANT BIOTECHNOLOGIES, LLC, COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GAMBRO BCT, INC.;REEL/FRAME:019136/0637

Effective date: 20070313

AS Assignment

Owner name: CARIDIANBCT BIOTECHNOLOGIES, LLC., COLORADO

Free format text: CHANGE OF NAME;ASSIGNOR:NAVIGANT BIOTECHNOLOGIES, LLC;REEL/FRAME:021301/0079

Effective date: 20080714

AS Assignment

Owner name: CITICORP TRUSTEE COMPANY LIMITED, UNITED KINGDOM

Free format text: IP SECURITY AGREEMENT SUPPLEMENT;ASSIGNOR:CARIDIANBCT BIOTECHNOLOGIES, LLC;REEL/FRAME:022714/0560

Effective date: 20090131

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION

AS Assignment

Owner name: CARIDIANBCT BIOTECHNOLOGIES, LLC, COLORADO

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CITICORP TRUSTEE COMPANY LIMITED, AS SECUIRTY AGENT;REEL/FRAME:026737/0537

Effective date: 20110727